**Name of journal: World Journal of Cardiology**

**ESPS Manuscript NO: 8922**

**Columns:**Review

Serum creatinine role in predicting outcome after cardiac surgery beyond acute kidney injury

Najafi M.Creatinine, AKI and cardiac surgery outcome

Mahdi Najafi

**Mahdi Najafi,** Tehran Heart Center, Tehran University of Medical Sciences, Tehran 1411713138, Iran

**Author contributions:** Najafi M solely contributed to this paper.

**Correspondence to: Mahdi Najafi MD,** Tehran Heart Center, Tehran University of Medical Sciences, North Karegar Ave, Tehran 1411713138, Iran. najafik@sina.tums.ac.ir

**Telephone**: +98-21-88029674  **Fax:** +98-21-88029724

**Received:** January 11, 2014  **Revised:** April 7, 2014

**Accepted:** July 12, 2014

**Published online:**

**Abstract**

Serum creatinine is still the most important determinant in the assessment of perioperative renal function and in the prediction of adverse outcome in cardiac surgery. Many biomarkers have been studied to date; still, there is no surrogate for serum creatinine measurement in clinical practice, because it is feasible and inexpensive. High level of serum creatinine and its equivalents have been the most important preoperative risk factor for postoperative renal injury. Moreover, creatinine is mainstay in predicting risk models and risk factor reduction has enhanced its importance in outcome prediction. Future perspective is the development of new definitions and novel tools for the early diagnosis of acute kidney injury largely based on serum creatinine and a panel of novel biomarkers.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

**Key words**: Creatinine; Acute kidney injury; Cardiac surgery; Outcome; Biomarker

**Core tip:** This manuscript aims to review the latest achievements in the diagnosis and treatment of acute kidney injury (AKI). Despite much progress in recent years especially in development of novel biomarkers, serum creatinine still plays the major role. Creatinine is not only the mainstay of definition, diagnosis and prediction of AKI, but also the most important predictor of outcome after cardiac surgery, including mortality and morbidity as well as hospital length of stay.

Najafi M. Serum creatinine role in predicting outcome after cardiac surgery beyond acute kidney Injury. *World J Cardiol* 2014; In press

**INTRODUCTION**

Creatinine is an important determinant in cardiac surgery. Rise in the level of serum creatinine has a significant impact on surgical outcome. Acute kidney injury (AKI) is basically defined by perioperative changes in serum creatinine level. Even minimal changes in serum creatinine that are not high enough to be defined as AKI, worsen the outcome of patients who undergo cardiac surgery. Sensitivity of serum creatinine is low and its response to renal insult is slow and late. However, serum creatinine level still constitutes the main measure for the assessment of renal function thanks to the simplicity and availability of its measurement. Similarly, serum creatinine is the cornerstone of the consensus definitions of AKI. Indeed, RIFLE, AKIN and KDIGO all use creatinine for grading the severity of AKI[1,2]. Principal role of creatinine as a main predicting factor in the scoring systems for risk estimation is well known[3]. Creatinine has, therefore, been included in the first three important risk factors for mortality after cardiac surgery by newer prediction scores[4].

With little tolerance, we assume an abrupt rise in serum creatinine as acute kidney injury (AKI). Due to the unique characteristics and specifications of AKI that occurs after cardiac surgery, it has been called cardiac surgery associated AKI (CSA-AKI). In recent years many investigations have been performed to find answers to key questions on the prevention and treatment of CSA-AKI in the perioperative period. Numerous studies have been performed and are underway with their focus on the CSA-AKI[2, 5] and there are promising results especially in prophylactic management. However, recruitment of patients with minimum risk of AKI for clinical trials on CSA-AKI treatment is the main reasons why most of these studies lack the sufficient power to be conclusive[2, 5]. Furthermore, inconsistency in the definition of AKI between different studies makes it difficult to analyze the results of these studies in meta-analyses[5, 6].

This review covers the following grounds: (1) Association of serum creatinine with cardiac surgery-associated mortality and morbidity; (2) Serum creatinine role in diagnosis of cardiac surgery-associated acute kidney injury; (3) Risk factors for high perioperative serum creatinine; (4) Risk models for AKI after cardiac surgery; (5) Creatinine and the outcome prediction in cardiac surgery; and (6) Prevention and treatment on the horizon.

**ASSOCIATION OF SERUM CREATININE WITH CARDIAC SURGERY-ASSOCIATED MORTALITY AND MORBIDITY**

The development of postoperative AKI has been recognized as the strongest risk factor for death in patients undergoing cardiac surgery[7]. It has been shown that AKI occurs in up to 40% of patients undergoing cardiac surgery[2]. As much as the incidence is rare (1% to 5%), mortality among patients with AKI who require renal replacement therapy (RRT) or become dialysis dependent is more than 50% and approaches 80% in patients who need dialysis, while the overall mortality rate after cardiac surgery hardly exceeds 8%[7-9].

AKI increases postoperative morbidity, length of stay in the intensive care unit (ICU) and hospital and costs of care[10]. High level of preoperative serum creatinine is associated with higher risk of RRT and need for dialysis after cardiac surgery[11, 12]. Even minimal changes in serum creatinine increases postoperative mortality significantly. Indeed 30 day mortality was reported 2.8 and 18.6 fold higher with up to 0.5 mg/dL and more than 0.5 g/dL creatinine rise, respectively, compared to no change in a group of patients who underwent cardiac surgery[13]. The risk of AKI increases in valvular and combined surgery compared to myocardial revascularization two to four times, respectively[11, 14, 15].

It has been indicated repeatedly in different studies that serum creatinine rise after cardiac surgery is followed by long-term CKD and mortality[16-19]. Moreover, higher degrees of preoperative kidney insufficiency are accompanied by a proportionally higher risk of CSA-AKI and need for RRT[20]. Pathophysiological studies indicate that cardiac patients with AKI are more likely to have progressive renal changes beyond the acute episode even after reduction of serum creatinine to normal levels[19, 21, 22].

AKI has been divided into pre-renal, renal, and post-renal with regard to etiology. In surgical patients, pre-renal etiology, followed by renal etiology, is the most common causes of AKI[23]. As volume changes are common during cardiac surgery, CSA-AKI can be divided into volume responsive and non-volume responsive which usually matches pre-renal and renal etiologies. Renal etiology of CSA-AKI is caused by various factors including ischemia and ischemia-reperfusion injury, inflammation and oxidative stress, exogenous and endogenous toxins, metabolic abnormalities and neurohormonal activation[24]. They can briefly divided into hemodynamic, inflammatory, and nephrotoxic factors[25, 26].

**SERUM CREATININE ROLE IN DIAGNOSIS OF CARDIAC SURGERY-ASSOCIATED ACUTE KIDNEY INJURY**

In this section, we have discussed that new equations have improved the calculation of eGFR especially in people with suboptimal kidney function and near normal real GFR. Moreover, new consensus systems are focused on more accurate practical definitions of AKI so that they can be better tools for outcome prediction. Nonetheless, there are obstacles to employing these formulas and definitions in cardiac surgery and creatinine still rules supreme.

Kidney impairment after cardiac surgery is acute in onset and most probably occurs in patients without a previous history of renal insufficiency. However, conventional formulas for glomerular filtration rate estimation (eGFR) have been released by studies on patients with renal impairment. Similarly, well-known definitions of AKI have been developed by analyzing data from patients with previous chronic kidney disease (CKD). Paradoxically, most of the studies on AKI diagnosis and management after cardiac surgery have been performed in people without CKD, while we know CKD is the most important predictor of postoperative AKI. This shows how challenging it is to study the most important complication of cardiac surgery.

***Creatinine clearance and glomerular filtration rate estimation methods***

Serum creatinine has been used to determine glomerular filtration rate (GFR) for a long time. Even the diagnosis and staging of CKD has been made through serum creatinine measurement. However, the serum concentration of creatinine is affected by factors such as age, gender, ethnicity, diet, muscle mass and medication. Moreover, creatinine will not be higher than the normal range until 50% of renal function is lost[27]. Direct measurement of GFR with inulin or radionuclides is expensive and complex and thus not suitable for routine use. Furthermore, the older method of 24 h urine sampling for the measurement of creatinine clearance is not easy to perform and the results are biased owing to some tubular secretion of creatinine that causes up to 40% overestimation of GFR compared to inulin clearance[27]. That is why better tools for the assessment of GFR are required.

There are several creatinine-based formulas for the estimation of GFR that are widely used in research and clinical practice. The Cockcroft-Gault (CG) formula which is named after the two scientists who developed it in 1976, is the most common surrogate for creatinine clearance in the estimation of GFR[28]. This formula employs age and weight as well as gender to calculate estimated GFR (eGFR). The formula is useful due to simplicity and ease of calculation and. It underscores the importance of age in estimating GFR: for the same level of creatinine, eGFR decreases to half at age 80 compared to the age 20. However, the use of this simple equation in obese patients was not possible. Accordingly, ideal body weight, which is calculated taking height into the account, is utilized in this group of people. Similarly, using adjusted body weight again while considering the role of height improves the GFR estimation in the elderly[29]. These shortcomings limit its application in the laboratory to report creatinine clearance.

Another common formula was developed by the Modification of Diet in Renal Disease (MDRD) Study Group in 1999[30]. It was simplified in 2002 by omitting albumin and blood urea nitrogen to a 4-variable MDRD which estimates GFR using the variables of age, gender, race and serum creatinine[31]. Laboratories use this formula to report eGFR. This formula estimates GFR more precisely in patients with CKD. Nevertheless, both 6-variable and 4-variable MDRDs underestimate GFR in healthy individuals with creatinine clearance more than 60 mL/min. Furthermore, compared to the Cockcroft-Gault equation, MDRD do not adjust for body mass index and thus underestimates GFR in obese and overestimates GFR in underweight people[32, 33].

The most important shortcoming of both Cockcroft-Gault and MDRD equations is their development in patients with CKD. What is more, it has been shown that both formulas have lower precision in people with normal GFR[33-35]. Cockcroft-Gault overestimates and MDRD underestimates GFR in this group of healthy population[36]. Renal insufficiency in cardiac surgery is acute in onset and most probably in patients without any history of CKD. These formulas may, therefore, not be as useful in this group of patients[37]. To overcome this problem, the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) developed a new formula in 2009. This equation is superior to MDRD when GFR is more than 60 mL/min. Unlike the other two formulas, CKD-EPI was developed through several studies in populations with suboptimal renal function[38]. Advantageous in the CKD-EPI equation is its probable improved cardiovascular risk prediction compared to MDRD in a middle-age population[39]. Findings in previous studies may probably need revision through a new[40].

Development of new equations and making modifications to the available ones reflects the attempts to make eGFR an ideal surrogate for real GFR as much as possible. However, the closer we get to an accurate estimate of GFR, the farther we get from a clinically more practical tool. The most important drawback to employing these formulas in clinical practice is the fact that we cannot find a formula to fit all clinical conditions. Accuracy of eGFR is compromised when the clinical condition is different from the populations from which the equations were derived. Malnutrition or reduction in muscle mass from illness or amputation, extremes of muscle mass and diet (such as vegetarianis), different ethnicities from those included in studies used for the development of the equations, or changes in the non-GFR determinants over time are the most probable determinants of large differences between real and estimated GFR[27, 34].

Newer concept is to add laboratory parameters that are not dependent on body muscle mass and nutrition so as to obtain a better estimation of GFR. Using cystatin C, an index of glomerular function, is believed to be promising in different investigations in adults and children[34, 41, 42]. There are even equations based on cystatin C to calculate GFR[42, 43]. However, cystatin C needs adjustment for age, gender and race too, although adjusted Cystatin C is probably superior to adjusted creatinine in developed equations[44]. Moreover, the lack of an international standard to calibrate cystatin C limits the use of these equations. More to the point, we do not know whether the routine use of cystatin C merits its cost as there is no evidence that it improves outcome significantly[45].

***Preoperative creatinine and occult renal insufficiency***

Discussion on preoperative creatinine revolves around the most important risk factor for CSA-AKI which is previous renal insufficiency[8, 46]. Nevertheless, no unique level of serum creatinine as a threshold for renal insufficiency has been defined[47]. Predictor models for AKI are not consistent too: although most of them have reported preoperative renal insufficiency as a risk factor, their definitions for renal insufficiency are largely diverse from baseline creatinine of 1.5 mg/dL and eGFR of 60 mL/min as cut points to dialysis dependency[48]. This holds true for most of the predictor models of outcome in cardiac surgery that have included preoperative renal insufficiency as a predictor[3, 4, 49]. Proteinuria, most prevalent parameter used in definition of CKD, is also absent in most of them due to lacking of data on urine analysis[5].

There is no debate on patients who are dialysis dependent or need renal replacement therapy. We recognize these problems as kidney disease. The most challenging are the patients whose serum creatinine level is within normal range but their real GFR or eGFR is low. We call this condition occult renal insufficiency and it is usually defined as eGFR <60 mL/min when creatinine is in normal range. Several studies have shown that the incidence of morbidity and mortality after cardiac surgery is higher in patients with occult renal insufficiency[50-53].

***Acute kidney Injury definition systems: RIFLE, AKIN, and KDIGO***

Despite the recognized importance of AKI, one of the major problems in conducting studies on the subject is the lack of consensus regarding the diagnosis, as there are more than 30 different definitions for AKI[47]. In the past decade several consensus systems have been introduced to define AKI uniformly in different studies. Perioperative changes in the serum concentration of creatinine are the cornerstone of the definition in these systems. In 2004, the RIFLE criteria (an acronym for: Risk of renal failure, Injury to the kidney, Failure of kidney function, Loss of kidney function, and End-stage renal failure) were proposed by the Acute Dialysis Quality Initiative (ADQI) group[47].

A revised version of the RIFLE criteria was suggested by the Acute Kidney Injury Network (AKIN) group in 2007. There are four main changes in AKIN compared to RIFLE (Table 1): GFR changes have been omitted from the definition system, time period of seven days for creatinine changes has been replaced by 48 h, creatinine changes as low as 0.3 mg/dL is the lowest measure to be considered as AKI and the two outcome determinants in RIFLE (loss and end stage) are deleted to define AKI in three stages[54].

Following the establishment of the AKIN scoring system, the resultant debate over the supremacy of each criterion prompted comparative research[55-60], which disclosed that AKIN was not more efficient than RIFLE and even some authors still preferred to employ RIFLE with some modifications[55]. Modified RIFLE stages anyone who needs RRT in category F (failure) regardless of the level of serum creatinine. A recent study performed with this method reported an incidence of 14% for AKI and showed that CSA-AKI aggravated short term and long term outcomes in cardiac patients[19]. Nevertheless, a large survey of 1881 patients by Bastin *et al* indicated that the incidence of AKI with both AKIN and RIFLE criteria was mostly equal (25.9% and 24.9%, respectively), but hospital mortality was predicted more precisely by AKIN[61]. Another dispute was over the sensitivity of the two definitions insofar as whether or not the designated thresholds sufficiently diagnose all the cases of renal impairment. Studies have shown that there are concerns about the adequacy of the AKIN and RIFLE criteria inasmuch as by the current standards, some AKI cases may be left undiagnosed. Lassing *et al*[62] described a new scoring system and reported that determining the amount of serum creatinine (SCr) changes within 48 h was more capable than the RIFLE or AKIN criteria in predicting post-surgical outcomes.

This idea and the results of other studies encouraged the researchers to propose a new definition. The Kidney Disease: Improving Global Outcomes (KDIGO) workgroup has recently reviewed these criteria and published a single definition for use in both clinical practice and research. AKI is defined when any of the following three criteria are met; an increase in serum creatinine by 50% in seven days, an increase in serum creatinine greater than 0.3 mg/dL in 48 h or oliguria[1]. There is paucity of data to judge KDIGO as few studies have employed this criterion to date[63, 64]. However, AKI incidence using KDIGO definition is probably lower than that using AKIN and RIFLE. Reported incidences of AKI in different studies ranged 26%-49% for AKIN[55, 60], 19%-30% for RIFLE[55, 60], and 15%-16% for KDIGO[63, 64].

Thanks to the development of consensus systems for the definition of AKI, it is possible currently to compare studies around the world and newer definitions have improved their employment in cardiac patients. Nevertheless, we are still far from an ideal practical definition of CSA-AKI. One reason may be the effect of the minimal changes in creatinine on outcome. Though this has been investigated largely in patients undergoing cardiac surgery[13, 62], it is not limited to cardiac patients[65]. The AKIN definition sets a lower minimum level of serum creatinine as the diagnosis cut-point for AKI. However, even people who lie out of minimum level have worse outcome compared to patients with almost no change in serum creatinine. As employing the current systems for AKI definition in clinical practice is not easy, many of the studies having been performed to date have utilized these definitions partially. This is probably more pronounced in the RIFLE criteria which require seven days follow-up for the diagnosis to be completed[66].

***AKI biomarkers, creatinine as a biomarker***

**Conventional biomarkers:** An ideal biomarker for AKI is noninvasive, specific and sensitive for the detection of AKI within 24 h, and is detected and measured in a rapid and reproducible way. Moreover, it should stratify risk and identify AKI subtypes[1, 27, 67, 68]. A single biomarker that can fulfill all these criteria has yet to emerge[69]. Serum creatinine as a biomarker is still the only reliable tool for the assessment of AKI. Urine output is readily available and more sensitive to hemodynamic changes compared to creatinine. However, its variations are not specific especially during cardiac surgery with cardiopulmonary bypass (CPB) and unavoidable hemodynamic changes due to medications such as diuretics, mannitol and other fluids and possible measures such as ultrafiltration. In addition, the well- known term of non-oliguric renal failure denotes that normal urine output does not guarantee normal renal function[70, 71]. The other marker, urinanalysis, can differentiate prerenal from renal failure in patients with decreased urine output which is very helpful in guiding treatment. Obviously urinanalysis is not suitable for prophylactic measures due to its delayed response to renal insult[71].

With regard to eGFR formulas, we know that there is a lag between the renal event and serum creatinine changes that may be as long as 48 h, while we expect to know the occurrence of renal impairment immediately after surgery. As creatinine is not a sensitive measure, GFR may decreases up to 50% before the creatinine starts to change. Moreover, as creatinine is not specific, its value is influenced by changes in age, gender, race and muscle mass as was discussed before. In cardiac surgery, changes in total body volume, protein intake and medications may extend the list[27, 72]. These factors are so important that, for instance, volume overload was reported to be superior to creatinine in predicting outcome after cardiac surgery in a recent study[73].

**Novel biomarkers:** Using the most sensitive and specific biomarker for AKI is the ideal solution for the optimal estimation of GFR and rapid diagnosis of renal insult. As was noted, such a biomarker should be biologically stable and as a laboratory assay should be quick, reliable and cost effective with a high discriminative power[67]. So important is this issue that finding a suitable biomarker was recommended as the key search area in 2005[74]. Currently, two large studies are underway to assess the role of novel biomarkers in the diagnosis and prognosis of AKI: multicenter National Heart, Lung and Blood Institute–sponsored Translational Research Investigating Biomarker Endpoints in AKI (TRIBE-AKI) study and The Assessment, Serial Evaluation, and Subsequent Sequelae of Acute Kidney Injury (ASSESS-AKI) study. The latter is aimed at evaluation of long term complications of AKI too[75]. The results of these large studies are expected to shed sufficient light on the matter.

In recent years, more than 20 biomarkers have been introduced and most of them have been tested in studies of post-cardiac surgery[68,76]. Four novel biomarkers have been studied most frequently: neutrophil gelatinase-associated lipocalin (NGAL), interlukin-18 (IL-18), kidney injury molecule-1(KIM-1) as markers of tubular injury and cystatin C as a marker of glomerular function. NGAL, followed by IL-18, is more promising as an early diagnostic tool and it may qualify for entry into clinical practice. KIM-1 has delayed response and cystatin C needs adjustment for age, gender and race[2, 69, 77].

**Neutrophil gelatinase-associated lipocalin:** NGAL is a protein that normally binds to small iron-carrying molecules. NGAL is significantly upregulated in response to renal tubular injury. Role of NGAL in the diagnosis of AKI has been the most extensively studied in cardiac surgery[78]. First, animal studies in 2003 showed that NGAL was markedly upregulated early after ischemic injury[79]. Then its rapid rise following renal insult drew attentions. Level of urinary NGAL one hour post-CPB significantly predicted the risk of AKI after cardiac surgery[80]. Plasma NGAL levels two hours after CPB were strongly correlated with the duration and severity of AKI[81]. Other studies showed that NGAL levels were predictive of CSA-AKI when measured both in urine and plasma[82-85].

It is noteworthy that the predictive power of NGAL in pediatric surgery is striking, whereas its sensitivity and specificity for AKI prediction in adult cardiac surgery is not high enough to employ it as the sole biomarker for CSA-AKI[78, 86] It shows that the nature of CSA-AKI in adults is probably more complex. Degrees of chronic renal impairment before cardiac surgery may explain part of this inconsistency between the response of biomarkers to renal insult in adults and children. It is evident from recent studies that the diagnostic performance of NGAL is significantly influenced by baseline renal function[84, 87].

**Interlukin-18:** IL-18, a pro-inflammatory cytokine, is a biomarker of AKI and it is detectable in urine four to six hours after CPB peaking at 12 h [88]. A multi-center study showed that plasma NGAL and urine IL-18 peaking within 6 h after cardiac surgery not only predicted AKI earlier than serum creatinine but also predicted important outcomes such as length of stay in the ICU and hospital, dialysis, and death[89].

However, there are some challenges vis-à-vis the use of the currently available biomarkers: First, biomarkers are being evaluated in comparison with creatinine as a gold standard while the weakness of serum creatinine to be a sensitive and specific marker has been the main cause of directing research into finding novel biomarkers[90]. Second, many of the studies having been undertaken to date have excluded patients with CKD[70] while CKD is the most important risk factor for postoperative AKI. Discrepancy between clinical practice and the results of research may arise as biomarkers are under the influence of baseline renal function[11, 12]. Third, the level of biomarkers increases in response to injury. Though novel biomarkers are superior due to earlier response, the ideal biomarker would be one that predicts AKI preoperatively. Promising results have been reported by ouabain[91]. Forth, the pathogenesis of AKI is multifactorial. Hemodynamic, inflammatory, and nephrotoxic factors are responsible and overlap each other in leading to kidney injury[25]. This complex pathology affects finding a unique biomarker with high accuracy in diagnosis of AKI. Consequently, none of the biomarkers by itself is an accurate and reliable predictor for the diagnosis and risk estimation in AKI. Combination of biomarkers as a diagnostic panel would probably allow the determination of the risk and the severity as well as the early diagnosis of AKI[76, 92].

**RISK FACTORS FOR HIGH PERIOPERATIVE SERUM CREATININE**

Risk factors for increased level of serum creatinine and the development of AKI have been widely studied[10, 71]. There are two main groups of risk factors: preoperative and intraoperative. Most of the preoperative risk factors are patient-related and most of the intraoperative risk factors are procedure-related. Usually, intraoperative risk factors are more likely to be modifiable[25] (Table 2). Postoperative factors such as blood drainage and need for excessive transfusion and emergent exploration as well as myocardial infarction are of limited interest due to late onset and low chance of their benefit in AKI prediction and prevention[10].

***Preoperative risk factors***

Preoperative risk factors are not the same in different studies. Most reported risk factors include advanced age, female gender, New York Heart Association Function class IV, reduced left ventriclar ejection fraction or congestive heart failure, diabetes mellitus, poor glycemic control, peripheral vascular disease and chronic obstructive pulmonary disease. Other factors such as need for preoperative intra-aortic balloon pump and pulmonary rales have been noted in studies. However, the most predictive risk factor has consistently been preoperative renal dysfunction[2, 71]. Thakar *et al*[14] developed a risk index for predicting the need for dialysis after cardiac surgery based on preoperative factors. This study showed that the value of preoperative serum creatinine as an equivalent for renal dysfunction is the most important predictor for AKI.

Several studies have suggested that medications such as non-steroidal anti-inflammatory drugs (NSAID) and angiotensin receptor blockers (ARB) be stopped before cardiac surgery in order to decrease the risk of AKI[25]. More recently, genetic predisposition to AKI has been studied. According to many polymorphism studies, apolipoprotein was associated with AKI and its epsilon-4 allele has been the only genotype protective against AKI compared to other forms of allele[93, 94].

***Intraoperative risk factors***

Contrary to many preoperative risk factors that are well known for their role in the development of CSA-AKI, the identification of intraoperative risk factors is challenging. Maintaining hemodynamics stable is probably the most important point in kidney protection during cardiac surgery especially on the CPB. This is supported by the finding that many of intraoperative risk factors are associated with hemodynamic instability: low-output syndrome; intraoperative intra-aortic balloon pump use; pressor need prior to CPB; and need for deep hypothermic circulatory arrest. However, the management of hemodynamic changes is not easily feasible because patient factors such as venous compliance, systemic vascular resistance, and autoregulatory systems are responsible for cardiovascular stability during cardiac surgery and are difficult to control for[10].

Rather than surgery type (valvular, re do, emergency), modifiable procedure-related risk factors include on-pump cardiac surgery, CPB nonpulsatile flow and hypothermic CPB. Current data is insufficient to confirm the association between these CPB parameters and risk of CSA-AKI[2, 71]. Other more established CPB-related risk factors are duration of CPB (> 100-120 min), perfusion pressure, hemodilution during CPB, blood transfusion, hemolysis which is most commonly due to cardiotomy suction, and embolism[2, 95, 96]. Role of CPB in inducing systemic inflammatory response syndrome (SIRS) and consequently CSA-AKI has been shown in different cardiac surgery events. The inflammation is related to perfusion pressure, hemodilution, blood transfusion, hypothermia, hemolysis and embolism[97, 98]. SIRS and other physiologic untoward events explain how much longer CPB time increases the incidence of CSA-AKI. A meta-analysis in 2009 showed that mean CPB time and mean cross clamp time were significantly longer in patients who developed AKI. No safe time limit has been reported, however[99].

***Surgical tecnique***

Surgical techniques with minimum CPB usage potentially lessen the adverse complications of inflammatory response. Minimally invasive cardiac surgery including transcatheter aortic valve implantation (TAVI) or minimally invasive mitral valve (MV) surgery decreases the incidence of AKI[100]. The other technique is mini CPB or miniaturized extracorporeal circuit with unproven efficacy in CSA-AKI prevention[101]. Off-pump coronary artery bypass (OPCAB) is another technique to ameliorate CPB-related complications and aortic manipulations. However, it is interesting that the effectiveness of OPCAB in preventing from CSA-AKI is controversial and it is still one of the most debated topics in cardiac surgery. Though OPCAB has been shown to be superior in many studies[102-105], the results of recent large trials results have documented that it does not decrease important endpoints, especially the need for RRT[106, 107]. This may place an emphasis on the importance of hemodynamic stability in AKI prevention on account of the fact that during OPCAB, episodes of hypotension are inevitable. Overall, we conclude that at least in patients with lower risk for AKI, OPCAB may not decrease the likelihood of kidney impairment after cardiac surgery.

***Hemodynamic***

Perioperative hypotension during CPB increases the incidence of CSA-AKI. It is more important to preserve end-organ function and cellular oxygen delivery during CPB with its unique pressure and non-pulsatile flow characteristics. Thus, this is not the absolute hypotension but perfusion pressure that plays a pivotal role in protecting susceptible organs such as the kidney against CSA-AKI. Kidney medulla is more vulnerable since it is oxygen delivery is already low[108, 109]. Difference between preoperative and intraoperative blood pressure may be a more important predictor of CSA-AKI compared to absolute hypotension. A study in 2010 showed that when this difference is more than 25 mmHg the incidence of CSA-AKI increases[110].

***Hemodilution***

Carrying capacity of oxygen is influenced by hemodilution which is inevitable during CPB. This adds to hemodynamic changes due to nonpulsatile flow and puts kidney at danger of ischemia[109]. It has been suggested that hematocrit levels less than 24% increase the risk of CSA-AKI[111-113]. However, in all probability, preoperative hematocrit plays an important role[114]. The most important factor is the balance between oxygen delivery and oxygen consumption which is crucial everywhere in the body and not least in the kidney, which is more susceptible to ischemia[24]. Even the probable risk of hypothermia during CPB may be explained by reperfusion ischemia due to rapid rewarming[115].

That hemodilution has some adverse effects does not mean that blood transfusion is absolutely beneficial in improving renal function. RBC storage more than 14 d has been associated with increased organ injury[116]. Moreover, the adverse effects of packed cell transfusion when hemoglobin level is not low outweigh its benefits[117, 118].

Evidence-based blood conservation techniques include increasing preoperative blood volume by drugs such as erythropoietin and decreasing postoperative blood loss (tranexamic acid and aminocaproic acid), preserving the patient’s own blood by autologous techniques such as predonation and intraoperative hemodilution, and intraoperative cell salvage[119].

***CPB flow***

Pulsatile flow is believed to improve renal function by decreasing peripheral vascular resistance, optimizing microcirculation and decreasing tissue edema[120, 121]. However, the inconsistent results of studies cannot support its routine use for protection against CSA-AKI[122-124].

**RISK MODELS FOR AKI AFTER CARDIAC SURGERY**

Identification and categorization of high-risk patients allows optimal decision-making for earlier intervention and better management, along with the identification of the patients who do not respond to conventional treatments. Risk prediction models can also be used as research tools to select high risk patients for performing studies on AKI. Several risk stratification models have been developed by research groups in patients undergoing different surgeries[11, 125].

As was discussed before, CSA-AKI has its own characteristics. Though some risk factors for AKI are common in general and cardiac surgery, the risk scores developed in general surgery population underestimate the risk of AKI in cardiac surgery[126]. There are several risk prediction models that have been developed in the field of cardiac surgery[11, 14, 15, 127-129, 130].

Chertow *et al*[11] developed the first risk score using a large population database in1997. This algorithm stratified preoperative risk for dialysis based on data from 43 medical centers gathered in the Continuous Improvement in Cardiac Surgery Study (CICSS). Then three other predictive risk models were developed, all of which were aimed at predicting the need for dialysis as outcome[14, 127, 128]. The most validated model with a high level of precision and the best discriminative power is the Cleveland Clinic Score which was published in 2005 by Thaker *et al*[14, 126, 131-133].

In 2006, the Society of Thoracic Surgeons (STS) Bedside Risk Tool was developed by Mehta *et al*[128] through the analysis of a multicenter dataset of more than 600 hospitals. Simplified Renal Index (SRI) was developed by Wijeysundra *et al*[127] from a Toronto cohort in 2007. Validation studies by other researchers indicate that recalibration of every risk score is needed for optimal risk prediction in any center[134-136]. Other available models are aimed at predicting AKI not requiring dialysis. They have not been externally validated, however, and due to different definitions of AKI it is difficult to generalize them[16, 129, 130].

The most important criticism to the available risk models is their lack of prediction for CSA-AKI. There are still different definitions for AKI and there is no guideline to recommend a specific prediction model[2, 48]. As was discussed before, we need to add novel biomarkers to the current risk models and AKI definitions so as to be able to develop scoring systems for the prediction of the earlier stages of AKI. A study by Parikh *et al*[89] indicated that adding urine IL-18 and plasma NGAL to the risk models improved risk prediction by 25% and 18% respectively.

**CREATININE AND THE OUTCOME PREDICTION IN CARDIAC SURGERY**

Critical role of creatinine as a strong predictor has been incorporated in the different mortality risk scores that are currently in use for cardiac surgery patients[3, 49, 137]. Known risk models have employed a wide range of risk factors from only three up to dozens[3, 4]. However, high level of serum creatinine or its equivalents (past history of kidney dysfunction, need for renal replacement therapy and/or dialysis) has been the constituent of almost all of them. The first scoring system was developed by Parsonnet *et al*[138] in 1989, which included serum creatinine in 14 independent variables. Subsequently, Higgins *et al* proposed the Cleveland Clinic score in 1992[139]. Cleveland Clinic score was basically developed for coronary artery bypass graft (CABG) operations with or without associated valve surgery and included creatinine among 9 independent variables included in this score. Another mortality predictor introduced in 1992 was the Northern New England score which was developed for isolated CABG operations included preoperative dialysis dependency as a surrogate for high serum level of creatinine[140]. Magovern *et al*[3, 141] developed another risk algorithm to be applied in isolated CABG with promising results compared to a group of 18 risk models.

In the last decade, the additive[142] and the logistic[143] EuroSCORE predicting tools were developed and subsequently widely validated. These scores are prepared to be applied in all cardiac surgeries in adult patients and each of them include 17 independent variables. Serum creatinine receives a score of two when its absolute value is more than 200 µmol/L (2.25 mg/dL). EuroSCORE overestimates mortality and its performance in high risk patients is not good. euroSCORE II was released in 2012 to improve the accuracy of this measure[144].

The risk score developed by the Society of Thoracic Surgeons is more complex built on a database with more than five million records and including several hundred variables[145]. The risk calculator is available freely at: <http://riskcalc.sts.org/STSWebRiskCalc273/>. On the opposite, recently Ranuchi *et al*[4] proposed a simple score with only three variables including creatinine and demonstrated that this risk model was superior to or as effective as the other more complex risk scoring systems. Creatinine in this score has an absolute cut point of 2 mg/dL. In patients with serum level of creatinine higher than 2 mg/dL, one point is added to sum of patient’s risk. The formula is as follows: age (years)/ejection fraction (%) +1 (if serum creatinine > 2 mg/dL).

The main weakness of existing risk models is their inaccuracy in different time periods and patients’ conditions and various regional settings which emphasizes on dynamic trends in cardiac surgery[146, 147]. Moreover, known risk models are principally prepared to predict mortality. So, we probably are unable to accurately predict morbidity and cost of care by available risk models. The other major flaw is lack of consensus definition of time span for mortality by these models[137].

**PREVENTION AND TREATMENT ON THE HORIZON**

Briefly, no treatment or prophylactic measure studied thus far has received sufficient evidence- based support to be employed in AKI management[66]. However, avoidance of AKI by preventive measures remains the mainstay of management in high risk patients. Contrast induced AKI (CI-AKI) is probably an exception in that it is preventable and manageable by hydration, N-acetyl cysteine and bicarbonate[148].

Renoprotective measures include preventive simple maneuvers such as avoidance of nephrotoxic drugs, hydration, glycemic control, maintenance of renal perfusion and goal directed therapy (GDT) as well as more advanced pharmacological interventions[1, 2, 70, 71] (Table 3).

***Preventive measures***

Renal injury can be mitigated by two approaches: preventing CSA-AKI from being superimposed on CKD by appropriate risk assessment and preventing subclinical or silent AKI from occurring before cardiac surgery. Management of the adverse effects of contrast dye is an example of the second approach. The role of contrast dye in the occurrence of CSA-AKI is well known and as it is not avoidable, the minimum possible dose of preferably newer non-ionic contrast with lower osmolality should be used[149, 150] Timing of surgery following contrast angiography may play a role in CSA-AKI. It has been shown that cardiac surgery within 24 hours of angiography is not safe. In case of large contrast dose administration it is better to postpone surgery for five days[151, 152] .

Sufficient hydration is protective not only in patients at risk of contrast-induced nephropathy[153] but also in patients with underlying renal insufficiency[154]. Ideal fluids have been thoroughly investigated to be recognized without consistent results[1, 71]. It appears from studies to date that colloids are not superior to crystalloids in improving outcome[155, 156]. Moreover, recent studies have shown that contrary to previous believes clinical application of semisynthetic colloids especially hydroxyethyl starch solutions (HES) are increasingly difficult to justify in the perioperative period[156]. Of more importance is probably maintaining normal renal perfusion as 80% of patients diagnosed with AKI after surgery have had an episode of perioperative hemodynamic instability[157]. GDT, involving the use of enough fluid and blood along with inotropes to optimize hemodynamic parameters and oxygen delivery, is a recommended strategy[156, 158, 159]. Fluids are required to be prescribed as drug[156]. This is possible through the employment of physiologic parameters such as the plethysmographic variability index (PVI), stroke volume variation (SVV) and pulse pressure variation (PPV) in advanced monitoring systems[159]. Further studies are needed to optimize protocols[156, 159].

Angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) are potential nephrotoxic medications commonly used in cardiac patients. Avoiding them has not been shown to change the incidence of CSA-AKI and the subject is still controversial[160, 161].

Other measures such as ischemic preconditioning using three 5-min intervals of ischemia separated by exactly same times and interval of reperfusion in the thigh, have been shown to reduce the risk of CSA-AKI[162].

***Pharmacologic interventions***

Finding a pharmacologic agent for the management of CSA-AKI has been challenging due to the absence of standard definitions and end-points[1, 2, 26, 70, 163]. Many drugs have been investigated to date to control the serum level of creatinine and renal protection. Fenoldopam, a selective agonist of dopamine-1 receptor, is the only drug that consistently and significantly has reduced the risk of AKI followed by Nesiritide with initial promising results[1, 164, 165].

Sodium bicarbonate was found in a known pilot study in 2009 to decrease the risk of AKI by 20%[166]. However, another large study in 2012 questioned its usefulness[167]. This is true for statins too. First reports on its usefulness were not supported by the following studies[168-171].

It is known since 2001 that low-dose Dopamine is not justified for both prevention and treatment of AKI[172, 173]. Furosemide infusion especially in combination with Dopamine is even detrimental and may increases postoperative creatinine[174, 175]. Mannitol, is an osmotic diuretic that has been used routinely in priming solution for decades. Currently there is debate on its usefulness in cardiac surgery and studies have been inconclusive. However, it is probably reasonable to continue its use as a harmless fluid until strong evidence, guidelines, and recommendations are published[176, 177].

Atrial natriuretic peptide (ANP) and brain-type natriuretic peptide (BNP) are endogenous diuretics with promising effects on renal function in cardiac surgery[178-180]. BNP is highly associated with postoperative AKI such that it has been considered as a biomarker for AKI in the recent report of TRIBE-AKI study[181]. Nesiritide, the recombinant human BNP, has been shown to be beneficial according to initial results. Further studies are required before applying Nesiritide routinely in daily clinical practice[182, 183].

N-Acetylcystein has protective effects on contrast-induced nephropathy[184]. Be that as it may, its prophylactic administration in cardiac surgery is under question. Recent meta-analyses have concluded that current data do not support its routine use in cardiac surgery and it has obtained least strength evidence among prophylactic measures for renal protection[1, 163, 185].

Current data is insufficient to support preoperative prophylactic RRT. The best starting time for postoperative RRT is controversial too. Most of the studies have found lower mortality with the earlier initiation of RRT[163, 186, 187]. In addition, recent guidelines suggest that using continuous RRT (CRRT) is superior to standard intermittent RRT in hemodynamically unstable patients[148]. It is clinically indicated and applicable, although reviews to date have not found differences in survival between the two modes[188]. similarly, the benefits of ultrafiltration on CSA-AKI prevalence and severity in adult cardiac surgery warrants further investigation.

**CONCLUSION**

Recent advances in diagnosis and management of CSA-AKI have opened new perspectives for scientists and medical practitioners. However, creatinine still plays the main role in diagnosis and prediction. New consensus classification for AKI (KDIGO) and new formula for eGFR calculation (CKD-EPI) are promising for better evaluation of patients at risk of postoperative AKI. Incorporating a panel of novel biomarkers in diagnosis and prevention could enhance the quality of the prediction and cause supportive care to be employed earlier. Results of large studies are expected to qualify the capability of these achievements to improve patients’ daily care. With respect to the AKI prevention and management, notwithstanding the large number of studies, more attempts are required to reach the optimal prophylactic and therapeutic goals.

**REFERENCES**

1 Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. *Kidney Inter Suppl* 2012; 2 (Supp 1): S1-S138.

2 **Mao H**, Katz N, Ariyanon W, Blanca-Martos L, Adýbelli Z, Giuliani A, Danesi TH, Kim JC, Nayak A, Neri M, Virzi GM, Brocca A, Scalzotto E, Salvador L, Ronco C. Cardiac Surgery-Associated Acute Kidney Injury. *Cardiorenal Med* 2013; **3**: 178-199 [PMID: 24454314 DOI: 10.1159/000353134]

3 **Nilsson J**, Algotsson L, Höglund P, Lührs C, Brandt J. Comparison of 19 pre-operative risk stratification models in open-heart surgery. *Eur Heart J* 2006; **27**: 867-874 [PMID: 16421172 DOI: 10.1093/eurheartj/ehi720]

4 **Ranucci M**, Castelvecchio S, Menicanti L, Frigiola A, Pelissero G. Risk of assessing mortality risk in elective cardiac operations: age, creatinine, ejection fraction, and the law of parsimony. *Circulation* 2009; **119**: 3053-3061 [PMID: 19506110 DOI: 10.1161/CIRCULATIONAHA.108.842393]

5 KDIGO clinical practice guideline for acute kidney injury online Appendices A-F March 2012. Available at: http: //www.kdigo.org/clinical\_practice\_guidelines/pdf/KDIGO-AKI-Suppl-Appendices-A-F\_March2012.pdf. Accessed January 1, 2014

6 **Hoste EA**, Cruz DN, Davenport A, Mehta RL, Piccinni P, Tetta C, Viscovo G, Ronco C. The epidemiology of cardiac surgery-associated acute kidney injury. *Int J Artif Organs* 2008; **31**: 158-165 [PMID: 18311732]

7 **Chertow GM**, Levy EM, Hammermeister KE, Grover F, Daley J. Independent association between acute renal failure and mortality following cardiac surgery. *Am J Med* 1998; **104**: 343-348 [PMID: 9576407 DOI: 10.1016/S0002-9343(98)00058-8]

8 **Thakar CV**, Worley S, Arrigain S, Yared JP, Paganini EP. Improved survival in acute kidney injury after cardiac surgery. *Am J Kidney Dis* 2007; **50**: 703-711 [PMID: 17954283 DOI: 10.1053/j.ajkd.2007.07.021]

9 **Mangano CM**, Diamondstone LS, Ramsay JG, Aggarwal A, Herskowitz A, Mangano DT. Renal dysfunction after myocardial revascularization: risk factors, adverse outcomes, and hospital resource utilization. The Multicenter Study of Perioperative Ischemia Research Group. *Ann Intern Med* 1998; **128**: 194-203 [PMID: 9454527 DOI: 10.7326/0003-4819-128-3-199802010-00005]

10 **Josephs SA**, Thakar CV. Perioperative risk assessment, prevention, and treatment of acute kidney injury. *Int Anesthesiol Clin* 2009; **47**: 89-105 [PMID: 19820480 DOI: 10.1097/AIA.0b013e3181b47e98]

11 **Chertow GM**, Lazarus JM, Christiansen CL, Cook EF, Hammermeister KE, Grover F, Daley J. Preoperative renal risk stratification. *Circulation* 1997; **95**: 878-884 [PMID: 9054745 DOI: 10.1161/01.CIR.95.4.878]

12 **Thakar CV**, Liangos O, Yared JP, Nelson DA, Hariachar S, Paganini EP. Predicting acute renal failure after cardiac surgery: validation and re-definition of a risk-stratification algorithm. *Hemodial Int* 2003; **7**: 143-147 [PMID: 19379354 DOI: 10.1046/j.1492-7535.2003.00029.x]

13 **Lassnigg A**, Schmidlin D, Mouhieddine M, Bachmann LM, Druml W, Bauer P, Hiesmayr M. Minimal changes of serum creatinine predict prognosis in patients after cardiothoracic surgery: a prospective cohort study. *J Am Soc Nephrol* 2004; **15**: 1597-1605 [PMID: 15153571 DOI: 10.1097/01.ASN.0000130340.93930.DD]

14 **Thakar CV**, Arrigain S, Worley S, Yared JP, Paganini EP. A clinical score to predict acute renal failure after cardiac surgery. *J Am Soc Nephrol* 2005; **16**: 162-168 [PMID: 15563569 DOI: 10.1681/ASN.2004040331]

15 **Palomba H**, de Castro I, Neto AL, Lage S, Yu L. Acute kidney injury prediction following elective cardiac surgery: AKICS Score. *Kidney Int* 2007; **72**: 624-631 [PMID: 17622275 DOI: 10.1038/sj.ki.5002419]

16 **Coca SG**, Yusuf B, Shlipak MG, Garg AX, Parikh CR. Long-term risk of mortality and other adverse outcomes after acute kidney injury: a systematic review and meta-analysis. *Am J Kidney Dis* 2009; **53**: 961-973 [PMID: 19346042 DOI: 10.1053/j.ajkd.2008.11.034]

17 **Ishani A**, Nelson D, Clothier B, Schult T, Nugent S, Greer N, Slinin Y, Ensrud KE. The magnitude of acute serum creatinine increase after cardiac surgery and the risk of chronic kidney disease, progression of kidney disease, and death. *Arch Intern Med* 2011; **171**: 226-233 [PMID: 21325112 DOI: 10.1001/archinternmed.2010.514]

18 **Hobson CE**, Yavas S, Segal MS, Schold JD, Tribble CG, Layon AJ, Bihorac A. Acute kidney injury is associated with increased long-term mortality after cardiothoracic surgery. *Circulation* 2009; **119**: 2444-2453 [PMID: 19398670 DOI: 10.1161/CIRCULATIONAHA.108.800011]

19 . Influence of acute kidney injury on short- and long-term outcomes in patients undergoing cardiac surgery: risk factors and prognostic value of a modified RIFLE classification. *Crit Care* 2013; **17**: R293 [PMID: 24330769 DOI: 10.1186/cc13159]

20 **Li SY**, Chen JY, Yang WC, Chuang CL. Acute kidney injury network classification predicts in-hospital and long-term mortality in patients undergoing elective coronary artery bypass grafting surgery. *Eur J Cardiothorac Surg* 2011; **39**: 323-328 [PMID: 20739188 DOI: 10.1016/j.ejcts.2010.07.010]

21 **Basile DP**. Rarefaction of peritubular capillaries following ischemic acute renal failure: a potential factor predisposing to progressive nephropathy. *Curr Opin Nephrol Hypertens* 2004; **13**: 1-7 [PMID: 15090853 DOI: 10.1097/00041552-200401000-00001]

22 **Manjunath G**, Tighiouart H, Ibrahim H, MacLeod B, Salem DN, Griffith JL, Coresh J, Levey AS, Sarnak MJ. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. *J Am Coll Cardiol* 2003; **41**: 47-55 [PMID: 12570944 DOI: 10.1016/S0735-1097(02)02663-3]

23 **Carmichael P**, Carmichael AR. Acute renal failure in the surgical setting. *ANZ J Surg* 2003; **73**: 144-153 [PMID: 12608979 DOI: 10.1046/j.1445-2197.2003.02640.x]

24 **Bellomo R**, Auriemma S, Fabbri A, D'Onofrio A, Katz N, McCullough PA, Ricci Z, Shaw A, Ronco C. The pathophysiology of cardiac surgery-associated acute kidney injury (CSA-AKI). *Int J Artif Organs* 2008; **31**: 166-178 [PMID: 18311733]

25 **Rosner MH**, Portilla D, Okusa MD. Cardiac surgery as a cause of acute kidney injury: pathogenesis and potential therapies. *J Intensive Care Med* 2008; **23**: 3-18 [PMID: 18230632 DOI: 10.1177/0885066607309998]

26 **Heringlake M**, Schön J, Paarmann H. The kidney in critical illness: how to monitor a pivotal organ system. *Best Pract Res Clin Anaesthesiol* 2013; **27**: 271-277 [PMID: 24012237 DOI: 10.1016/j.bpa.2013.06.003]

27 **Bagshaw SM**, Gibney RT. Conventional markers of kidney function. *Crit Care Med* 2008; **36**: S152-S158 [PMID: 18382187 DOI: 10.1097/CCM.0b013e318168c613]

28 **Cockcroft DW**, Gault MH. Prediction of creatinine clearance from serum creatinine. *Nephron* 1976; **16**: 31-41 [PMID: 1244564 DOI: 10.1159/000180580]

29 **Sokoll LJ**, Russell RM, Sadowski JA, Morrow FD. Establishment of creatinine clearance reference values for older women. *Clin Chem* 1994; **40**: 2276-2281 [PMID: 7988015]

30 **Levey AS**, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. *Ann Intern Med* 1999; **130**: 461-470 [PMID: 10075613 DOI: 10.7326/0003-4819-130-6-199903160-00002]

31 **National Kidney Foundation.** K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. *Am J Kidney Dis* 2002; **39**: S1-266 [PMID: 11904577]

32 **Gault MH**, Longerich LL, Harnett JD, Wesolowski C. Predicting glomerular function from adjusted serum creatinine. *Nephron* 1992; **62**: 249-256 [PMID: 1436333 DOI: 10.1159/000187054]

33 **Myers GL**, Miller WG, Coresh J, Fleming J, Greenberg N, Greene T, Hostetter T, Levey AS, Panteghini M, Welch M, Eckfeldt JH. Recommendations for improving serum creatinine measurement: a report from the Laboratory Working Group of the National Kidney Disease Education Program. *Clin Chem* 2006; **52**: 5-18 [PMID: 16332993 DOI: 10.1373/clinchem.2005.0525144]

34 **Stevens LA**, Coresh J, Greene T, Levey AS. Assessing kidney function--measured and estimated glomerular filtration rate. *N Engl J Med* 2006; **354**: 2473-2483 [PMID: 16760447 DOI: 10.1056/NEJMra054415]

35 **Coresh J**, Stevens LA. Kidney function estimating equations: where do we stand? *Curr Opin Nephrol Hypertens* 2006; **15**: 276-284 [PMID: 16609295 DOI: 10.1097/01.mnh.0000222695.84464.61]

36 **Lin J**, Knight EL, Hogan ML, Singh AK. A comparison of prediction equations for estimating glomerular filtration rate in adults without kidney disease. *J Am Soc Nephrol* 2003; **14**: 2573-2580 [PMID: 14514734 DOI: 10.1097/01.ASN.0000088721.98173.4B]

37 **Rule AD**, Larson TS, Bergstralh EJ, Slezak JM, Jacobsen SJ, Cosio FG. Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease. *Ann Intern Med* 2004; **141**: 929-937 [PMID: 15611490 DOI: 10.7326/0003-4819-141-12-200412210-00009]

38 **Levey AS**, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J. A new equation to estimate glomerular filtration rate. *Ann Intern Med* 2009; **150**: 604-612 [PMID: 19414839 DOI: 10.7326/0003-4819-150-9-200905050-00006]

39 **Matsushita K**, Selvin E, Bash LD, Astor BC, Coresh J. Risk implications of the new CKD Epidemiology Collaboration (CKD-EPI) equation compared with the MDRD Study equation for estimated GFR: the Atherosclerosis Risk in Communities (ARIC) Study. *Am J Kidney Dis* 2010; **55**: 648-659 [PMID: 20189275 DOI: 10.1053/j.ajkd.2009.12.016]

40 **Michels WM**, Grootendorst DC, Verduijn M, Elliott EG, Dekker FW, Krediet RT. Performance of the Cockcroft-Gault, MDRD, and new CKD-EPI formulas in relation to GFR, age, and body size. *Clin J Am Soc Nephrol* 2010; **5**: 1003-1009 [PMID: 20299365 DOI: 10.2215/CJN.06870909]

41 **Roos JF**, Doust J, Tett SE, Kirkpatrick CM. Diagnostic accuracy of cystatin C compared to serum creatinine for the estimation of renal dysfunction in adults and children--a meta-analysis. *Clin Biochem* 2007; **40**: 383-391 [PMID: 17316593 DOI: 10.1016/j.clinbiochem.2006.10.026]

42 **Schwartz GJ**, Muñoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, Furth SL. New equations to estimate GFR in children with CKD. *J Am Soc Nephrol* 2009; **20**: 629-637 [PMID: 19158356 DOI: 10.1681/ASN.2008030287]

43 **Chew JS**, Saleem M, Florkowski CM, George PM. Cystatin C--a paradigm of evidence based laboratory medicine. *Clin Biochem Rev* 2008; **29**: 47-62 [PMID: 18787643]

44 **Stevens LA**, Coresh J, Schmid CH, Feldman HI, Froissart M, Kusek J, Rossert J, Van Lente F, Bruce RD, Zhang YL, Greene T, Levey AS. Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. *Am J Kidney Dis* 2008; **51**: 395-406 [PMID: 18295055 DOI: 10.1053/j.ajkd.2007.11.018]

45 **Florkowski CM**, Chew-Harris JS. Methods of Estimating GFR - Different Equations Including CKD-EPI. *Clin Biochem Rev* 2011; **32**: 75-79 [PMID: 21611080]

46 **van Straten AH**, Soliman Hamad MA, van Zundert AA, Martens EJ, Schönberger JP, de Wolf AM. Preoperative renal function as a predictor of survival after coronary artery bypass grafting: comparison with a matched general population. *J Thorac Cardiovasc Surg* 2009; **138**: 971-976 [PMID: 19660275 DOI: 10.1016/j.jtcvs.2009.05.026]

47 **Bellomo R**, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. *Crit Care* 2004; **8**: R204-R212 [PMID: 15312219 DOI: 10.1186/cc2872]

48 **Huen SC**, Parikh CR. Predicting acute kidney injury after cardiac surgery: a systematic review. *Ann Thorac Surg* 2012; **93**: 337-347 [PMID: 22186469]

49 **Geissler HJ**, Hölzl P, Marohl S, Kuhn-Régnier F, Mehlhorn U, Südkamp M, de Vivie ER. Risk stratification in heart surgery: comparison of six score systems. *Eur J Cardiothorac Surg* 2000; **17**: 400-406 [PMID: 10773562 DOI: 10.1016/S1010-7940(00)00385-7]

50 **Wijeysundera DN**, Karkouti K, Beattie WS, Rao V, Ivanov J. Improving the identification of patients at risk of postoperative renal failure after cardiac surgery. *Anesthesiology* 2006; **104**: 65-72 [PMID: 16394692 DOI: 10.1097/00000542-200601000-00012]

51 **Najafi M**, Goodarzynejad H, Karimi A, Ghiasi A, Soltaninia H, Marzban M, Salehiomran A, Alinejad B, Soleymanzadeh M. Is preoperative serum creatinine a reliable indicator of outcome in patients undergoing coronary artery bypass surgery? *J Thorac Cardiovasc Surg* 2009; **137**: 304-308 [PMID: 19185142]

52 **Mitter N**, Shah A, Yuh D, Dodd-O J, Thompson RE, Cameron D, Hogue CW. Renal injury is associated with operative mortality after cardiac surgery for women and men. *J Thorac Cardiovasc Surg* 2010; **140**: 1367-1373 [PMID: 20381074 DOI: 10.1016/j.jtcvs.2010.02.021]

53 **Miceli A**, Bruno VD, Capoun R, Romeo F, Angelini GD, Caputo M. Occult renal dysfunction: a mortality and morbidity risk factor in coronary artery bypass grafting surgery. *J Thorac Cardiovasc Surg* 2011; **141**: 771-776 [PMID: 20884025 DOI: 10.1016/j.jtcvs.2010.08.016]

54 **Mehta RL**, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. *Crit Care* 2007; **11**: R31 [PMID: 17331245]

55 **Englberger L**, Suri RM, Li Z, Casey ET, Daly RC, Dearani JA, Schaff HV. Clinical accuracy of RIFLE and Acute Kidney Injury Network (AKIN) criteria for acute kidney injury in patients undergoing cardiac surgery. *Crit Care* 2011; **15**: R16 [PMID: 21232094]

56 **Ostermann M**, Chang RW. Challenges of defining acute kidney injury. *QJM* 2011; **104**: 237-243 [PMID: 20934982 DOI: 10.1093/qjmed/hcq185]

57 **Cruz DN**, Ricci Z, Ronco C. Clinical review: RIFLE and AKIN--time for reappraisal. *Crit Care* 2009; **13**: 211 [PMID: 19638179 DOI: 10.1186/cc7759]

58 **Bagshaw SM**, George C, Bellomo R. A comparison of the RIFLE and AKIN criteria for acute kidney injury in critically ill patients. *Nephrol Dial Transplant* 2008; **23**: 1569-1574 [PMID: 18281319 DOI: 10.1093/ndt/gfn009]

59 **Joannidis M**, Metnitz B, Bauer P, Schusterschitz N, Moreno R, Druml W, Metnitz PG. Acute kidney injury in critically ill patients classified by AKIN versus RIFLE using the SAPS 3 database. *Intensive Care Med* 2009; **35**: 1692-1702 [PMID: 19547955]

60 **Robert AM**, Kramer RS, Dacey LJ, Charlesworth DC, Leavitt BJ, Helm RE, Hernandez F, Sardella GL, Frumiento C, Likosky DS, Brown JR. Cardiac surgery-associated acute kidney injury: a comparison of two consensus criteria. *Ann Thorac Surg* 2010; **90**: 1939-1943 [PMID: 21095340 DOI: 10.1016/j.athoracsur.2010.08.018]

61 **Bastin AJ**, Ostermann M, Slack AJ, Diller GP, Finney SJ, Evans TW. Acute kidney injury after cardiac surgery according to Risk/Injury/Failure/Loss/End-stage, Acute Kidney Injury Network, and Kidney Disease: Improving Global Outcomes classifications. *J Crit Care* 2013; **28**: 389-396 [PMID: 23743540 DOI: 10.1016/j.jcrc.2012.12.008]

62 **Lassnigg A**, Schmid ER, Hiesmayr M, Falk C, Druml W, Bauer P, Schmidlin D. Impact of minimal increases in serum creatinine on outcome in patients after cardiothoracic surgery: do we have to revise current definitions of acute renal failure? *Crit Care Med* 2008; **36**: 1129-1137 [PMID: 18379238]

63 **Ho J**, Reslerova M, Gali B, Nickerson PW, Rush DN, Sood MM, Bueti J, Komenda P, Pascoe E, Arora RC, Rigatto C. Serum creatinine measurement immediately after cardiac surgery and prediction of acute kidney injury. *Am J Kidney Dis* 2012; **59**: 196-201 [PMID: 21967775 DOI: 10.1053/j.ajkd.2011.08.023]

64 **Sampaio MC**, Máximo CA, Montenegro CM, Mota DM, Fernandes TR, Bianco AC, Amodeo C, Cordeiro AC. Comparison of diagnostic criteria for acute kidney injury in cardiac surgery. *Arq Bras Cardiol* 2013; **101**: 18-25 [PMID: 23752340]

65 **Coca SG**, Peixoto AJ, Garg AX, Krumholz HM, Parikh CR. The prognostic importance of a small acute decrement in kidney function in hospitalized patients: a systematic review and meta-analysis. *Am J Kidney Dis* 2007; **50**: 712-720 [PMID: 17954284 DOI: 10.1053/j.ajkd.2007.07.018]

66 . Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). *Crit Care* 2013; **17**: 204 [PMID: 23394211]

67 **Garwood S**. Cardiac surgery-associated acute renal injury: new paradigms and innovative therapies. *J Cardiothorac Vasc Anesth* 2010; **24**: 990-1001 [PMID: 20702119 DOI: 10.1053/j.jvca.2010.05.010]

68 **Hall IE**, Coca SG, Perazella MA, Eko UU, Luciano RL, Peter PR, Han WK, Parikh CR. Risk of poor outcomes with novel and traditional biomarkers at clinical AKI diagnosis. *Clin J Am Soc Nephrol* 2011; **6**: 2740-2749 [PMID: 22034509 DOI: 10.2215/CJN.04960511]

69 **Wyckoff T**, Augoustides JG. Advances in acute kidney injury associated with cardiac surgery: the unfolding revolution in early detection. *J Cardiothorac Vasc Anesth* 2012; **26**: 340-345 [PMID: 22405191 DOI: 10.1053/j.jvca.2012.01.001]

70 **Calvert S**, Shaw A. Perioperative acute kidney injury. Perioperative Medicine 2012 1: 6.

71 **Moss E**, Lamarche Y. Acute Kidney Injury Following Cardiac Surgery: Prevention, Diagnosis, and Management, Renal Failure. The Facts, Dr. Momir Polenakovic (Ed.), 2012; ISBN: 978-953-51-0630-2, InTech, Available from: http: //www.intechopen.com/books/renal-failure-the-facts/acute-kidney-injuryfollowing-cardiac-surgery-prevention-diagnosis-and-treatment

72 **Mehta RL**, Chertow GM. Acute renal failure definitions and classification: time for change? *J Am Soc Nephrol* 2003; **14**: 2178-2187 [PMID: 12874474]

73 **Stein A,** de Souza LV, Belettini CR, Menegazzo WR, Viégas JR, Pereira EMC, Eick R, Araújo L, Consolim-Colombo F, Irigoyen MC.. Fluid overload and changes in serum creatinine after cardiac surgery: predictors of mortality and longer intensive care stay. A prospective cohort study. *Crit Care* 2012; **16**: R99 [PMID: 22651844]

74 . American Society of Nephrology Renal Research Report. *J Am Soc Nephrol* 2005; **16**: 1886-1903 [PMID: 15888557]

75 **Go AS**, Parikh CR, Ikizler TA, Coca S, Siew ED, Chinchilli VM, Hsu CY, Garg AX, Zappitelli M, Liu KD, Reeves WB, Ghahramani N, Devarajan P, Faulkner GB, Tan TC, Kimmel PL, Eggers P, Stokes JB. The assessment, serial evaluation, and subsequent sequelae of acute kidney injury (ASSESS-AKI) study: design and methods. *BMC Nephrol* 2010; **11**: 22 [PMID: 20799966]

76 **Ray P**, Le Manach Y, Riou B, Houle TT. Statistical evaluation of a biomarker. *Anesthesiology* 2010; **112**: 1023-1040 [PMID: 20234303]

77 **Coca SG**, Yalavarthy R, Concato J, Parikh CR. Biomarkers for the diagnosis and risk stratification of acute kidney injury: a systematic review. *Kidney Int* 2008; **73**: 1008-1016 [PMID: 18094679 DOI: 10.1038/sj.ki.5002729]

78 **Mishra J**, Dent C, Tarabishi R, Mitsnefes MM, Ma Q, Kelly C, Ruff SM, Zahedi K, Shao M, Bean J, Mori K, Barasch J, Devarajan P. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. *Lancet* 2005; **365**: 1231-1238 [PMID: 15811456 DOI: 10.1016/S0140-6736(05)74811-X]

79 **Mishra J**, Ma Q, Prada A, Mitsnefes M, Zahedi K, Yang J, Barasch J, Devarajan P. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. *J Am Soc Nephrol* 2003; **14**: 2534-2543 [PMID: 14514731]

80 **Wagener G**, Jan M, Kim M, Mori K, Barasch JM, Sladen RN, Lee HT. Association between increases in urinary neutrophil gelatinase-associated lipocalin and acute renal dysfunction after adult cardiac surgery. *Anesthesiology* 2006; **105**: 485-491 [PMID: 16931980 DOI: 10.1097/00000542-200609000-00011]

81 **Dent CL**, Ma Q, Dastrala S, Bennett M, Mitsnefes MM, Barasch J, Devarajan P. Plasma neutrophil gelatinase-associated lipocalin predicts acute kidney injury, morbidity and mortality after pediatric cardiac surgery: a prospective uncontrolled cohort study. *Crit Care* 2007; **11**: R127 [PMID: 18070344]

82 **Han WK**, Wagener G, Zhu Y, Wang S, Lee HT. Urinary biomarkers in the early detection of acute kidney injury after cardiac surgery. *Clin J Am Soc Nephrol* 2009; **4**: 873-882 [PMID: 19406962 DOI: 10.2215/CJN.04810908]

83 **Haase-Fielitz A**, Bellomo R, Devarajan P, Bennett M, Story D, Matalanis G, Frei U, Dragun D, Haase M. The predictive performance of plasma neutrophil gelatinase-associated lipocalin (NGAL) increases with grade of acute kidney injury. *Nephrol Dial Transplant* 2009; **24**: 3349-3354 [PMID: 19474273 DOI: 10.1093/ndt/gfp234]

84 **McIlroy DR**, Wagener G, Lee HT. Neutrophil gelatinase-associated lipocalin and acute kidney injury after cardiac surgery: the effect of baseline renal function on diagnostic performance. *Clin J Am Soc Nephrol* 2010; **5**: 211-219 [PMID: 20056755 DOI: 10.2215/CJN.04240609]

85 **Haase M**, Devarajan P, Haase-Fielitz A, Bellomo R, Cruz DN, Wagener G, Krawczeski CD, Koyner JL, Murray P, Zappitelli M, Goldstein SL, Makris K, Ronco C, Martensson J, Martling CR, Venge P, Siew E, Ware LB, Ikizler TA, Mertens PR. The outcome of neutrophil gelatinase-associated lipocalin-positive subclinical acute kidney injury: a multicenter pooled analysis of prospective studies. *J Am Coll Cardiol* 2011; **57**: 1752-1761 [PMID: 21511111 DOI: 10.1016/j.jacc.2010.11.051]

86 **Wagener G**, Gubitosa G, Wang S, Borregaard N, Kim M, Lee HT. Urinary neutrophil gelatinase-associated lipocalin and acute kidney injury after cardiac surgery. *Am J Kidney Dis* 2008; **52**: 425-433 [PMID: 18649981]

87 **Koyner JL**, Vaidya VS, Bennett MR, Ma Q, Worcester E, Akhter SA, Raman J, Jeevanandam V, O'Connor MF, Devarajan P, Bonventre JV, Murray PT. Urinary biomarkers in the clinical prognosis and early detection of acute kidney injury. *Clin J Am Soc Nephrol* 2010; **5**: 2154-2165 [PMID: 20798258]

88 **Parikh CR**, Mishra J, Thiessen-Philbrook H, Dursun B, Ma Q, Kelly C, Dent C, Devarajan P, Edelstein CL. Urinary IL-18 is an early predictive biomarker of acute kidney injury after cardiac surgery. *Kidney Int* 2006; **70**: 199-203 [PMID: 16710348]

89 **Parikh CR**, Coca SG, Thiessen-Philbrook H, Shlipak MG, Koyner JL, Wang Z, Edelstein CL, Devarajan P, Patel UD, Zappitelli M, Krawczeski CD, Passik CS, Swaminathan M, Garg AX. Postoperative biomarkers predict acute kidney injury and poor outcomes after adult cardiac surgery. *J Am Soc Nephrol* 2011; **22**: 1748-1757 [PMID: 21836143 DOI: 10.1681/ASN.2010121302]

90 **Waikar SS**, Betensky RA, Bonventre JV. Creatinine as the gold standard for kidney injury biomarker studies? *Nephrol Dial Transplant* 2009; **24**: 3263-3265 [PMID: 19736243]

91 **Bignami E**, Casamassima N, Frati E, Lanzani C, Corno L, Alfieri O, Gottlieb S, Simonini M, Shah KB, Mizzi A, Messaggio E, Zangrillo A, Ferrandi M, Ferrari P, Bianchi G, Hamlyn JM, Manunta P. Preoperative endogenous ouabain predicts acute kidney injury in cardiac surgery patients. *Crit Care Med* 2013; **41**: 744-755 [PMID: 23314581 DOI: 10.1097/CCM.0b013e3182741599]

92 **Han WK**, Waikar SS, Johnson A, Betensky RA, Dent CL, Devarajan P, Bonventre JV. Urinary biomarkers in the early diagnosis of acute kidney injury. *Kidney Int* 2008; **73**: 863-869 [PMID: 18059454]

93 **Chew ST**, Newman MF, White WD, Conlon PJ, Saunders AM, Strittmatter WJ, Landolfo K, Grocott HP, Stafford-Smith M. Preliminary report on the association of apolipoprotein E polymorphisms, with postoperative peak serum creatinine concentrations in cardiac surgical patients. *Anesthesiology* 2000; **93**: 325-331 [PMID: 10910477 DOI: 10.1097/00000542-200008000-00008]

94 **Lu JC**, Coca SG, Patel UD, Cantley L, Parikh CR. Searching for genes that matter in acute kidney injury: a systematic review. *Clin J Am Soc Nephrol* 2009; **4**: 1020-1031 [PMID: 19443624 DOI: 10.2215/CJN.05411008]

95 **Gude D**, Jha R. Acute kidney injury following cardiac surgery. *Ann Card Anaesth* 2012; **15**: 279-286 [PMID: 23041685]

96 **Fischer UM**, Weissenberger WK, Warters RD, Geissler HJ, Allen SJ, Mehlhorn U. Impact of cardiopulmonary bypass management on postcardiac surgery renal function. *Perfusion* 2002; **17**: 401-406 [PMID: 12470028 DOI: 10.1191/0267659102pf610oa]

97 **Rosner MH**, Okusa MD. Acute kidney injury associated with cardiac surgery. *Clin J Am Soc Nephrol* 2006; **1**: 19-32 [PMID: 17699187]

98 **Karkouti K**, Wijeysundera DN, Yau TM, Callum JL, Cheng DC, Crowther M, Dupuis JY, Fremes SE, Kent B, Laflamme C, Lamy A, Legare JF, Mazer CD, McCluskey SA, Rubens FD, Sawchuk C, Beattie WS. Acute kidney injury after cardiac surgery: focus on modifiable risk factors. *Circulation* 2009; **119**: 495-502 [PMID: 19153273 DOI: 10.1161/CIRCULATIONAHA.108.786913]

99 **Kumar AB**, Suneja M, Bayman EO, Weide GD, Tarasi M. Association between postoperative acute kidney injury and duration of cardiopulmonary bypass: a meta-analysis. *J Cardiothorac Vasc Anesth* 2012; **26**: 64-69 [PMID: 21924633 DOI: 10.1053/j.jvca.2011.07.007]

100 **Balaguer JM**, Umakanthan R, Leacche M, Byrne JG. Minimally invasive cardiac surgery. *Curr Probl Surg* 2012; **49**: 529-549 [PMID: 22883967 DOI: 10.1067/j.cpsurg.2012.06.002]

101 **Biancari F**, Rimpiläinen R. Meta-analysis of randomised trials comparing the effectiveness of miniaturised versus conventional cardiopulmonary bypass in adult cardiac surgery. *Heart* 2009; **95**: 964-969 [PMID: 19342377 DOI: 10.1136/hrt.2008.158709]

102 **Ascione R**, Nason G, Al-Ruzzeh S, Ko C, Ciulli F, Angelini GD. Coronary revascularization with or without cardiopulmonary bypass in patients with preoperative nondialysis-dependent renal insufficiency. *Ann Thorac Surg* 2001; **72**: 2020-2025 [PMID: 11789787 DOI: 10.1016/S0003-4975(01)03250-7]

103 **Beauford RB**, Saunders CR, Niemeier LA, Lunceford TA, Karanam R, Prendergast T, Shah S, Burns P, Sardari F, Goldstein DJ. Is off-pump revascularization better for patients with non-dialysis-dependent renal insufficiency? *Heart Surg Forum* 2004; **7**: E141-E146 [PMID: 15138092 DOI: 10.1532/HSF98.200330203]

104 **Nigwekar SU**, Kandula P, Hix JK, Thakar CV. Off-pump coronary artery bypass surgery and acute kidney injury: a meta-analysis of randomized and observational studies. *Am J Kidney Dis* 2009; **54**: 413-423 [PMID: 19406542 DOI: 10.1053/j.ajkd.2009.01.267]

105 **Chawla LS**, Zhao Y, Lough FC, Schroeder E, Seneff MG, Brennan JM. Off-pump versus on-pump coronary artery bypass grafting outcomes stratified by preoperative renal function. *J Am Soc Nephrol* 2012; **23**: 1389-1397 [PMID: 22595302 DOI: 10.1681/ASN.2012020122]

106 **Shroyer AL**, Grover FL, Hattler B, Collins JF, McDonald GO, Kozora E, Lucke JC, Baltz JH, Novitzky D. On-pump versus off-pump coronary-artery bypass surgery. *N Engl J Med* 2009; **361**: 1827-1837 [PMID: 19890125 DOI: 10.1056/NEJMoa0902905]

107 **Lamy A**, Devereaux PJ, Prabhakaran D, Taggart DP, Hu S, Paolasso E, Straka Z, Piegas LS, Akar AR, Jain AR, Noiseux N, Padmanabhan C, Bahamondes JC, Novick RJ, Vaijyanath P, Reddy S, Tao L, Olavegogeascoechea PA, Airan B, Sulling TA, Whitlock RP, Ou Y, Ng J, Chrolavicius S, Yusuf S. Off-pump or on-pump coronary-artery bypass grafting at 30 days. *N Engl J Med* 2012; **366**: 1489-1497 [PMID: 22449296 DOI: 10.1056/NEJMoa1200388]

108 **Parolari A**, Alamanni F, Gherli T, Bertera A, Dainese L, Costa C, Schena M, Sisillo E, Spirito R, Porqueddu M, Rona P, Biglioli P. Cardiopulmonary bypass and oxygen consumption: oxygen delivery and hemodynamics. *Ann Thorac Surg* 1999; **67**: 1320-1327 [PMID: 10355405 DOI: 10.1016/S0003-4975(99)00261-1]

109 **Haase M**, Bellomo R, Story D, Letis A, Klemz K, Matalanis G, Seevanayagam S, Dragun D, Seeliger E, Mertens PR, Haase-Fielitz A. Effect of mean arterial pressure, haemoglobin and blood transfusion during cardiopulmonary bypass on post-operative acute kidney injury. *Nephrol Dial Transplant* 2012; **27**: 153-160 [PMID: 21677302 DOI: 10.1093/ndt/gfr275]

110 **Kanji HD**, Schulze CJ, Hervas-Malo M, Wang P, Ross DB, Zibdawi M, Bagshaw SM. Difference between pre-operative and cardiopulmonary bypass mean arterial pressure is independently associated with early cardiac surgery-associated acute kidney injury. *J Cardiothorac Surg* 2010; **5**: 71 [PMID: 20825657 DOI: 10.1186/1749-8090-5-71]

111 **Habib RH**, Zacharias A, Schwann TA, Riordan CJ, Engoren M, Durham SJ, Shah A. Role of hemodilutional anemia and transfusion during cardiopulmonary bypass in renal injury after coronary revascularization: implications on operative outcome. *Crit Care Med* 2005; **33**: 1749-1756 [PMID: 16096452 DOI: 10.1097/01.CCM.0000171531.06133.B0]

112 **Huybregts RA**, de Vroege R, Jansen EK, van Schijndel AW, Christiaans HM, van Oeveren W. The association of hemodilution and transfusion of red blood cells with biochemical markers of splanchnic and renal injury during cardiopulmonary bypass. *Anesth Analg* 2009; **109**: 331-339 [PMID: 19608799 DOI: 10.1213/ane.0b013e3181ac52b2]

113 **Karkouti K**, Beattie WS, Wijeysundera DN, Rao V, Chan C, Dattilo KM, Djaiani G, Ivanov J, Karski J, David TE. Hemodilution during cardiopulmonary bypass is an independent risk factor for acute renal failure in adult cardiac surgery. *J Thorac Cardiovasc Surg* 2005; **129**: 391-400 [PMID: 15678051 DOI: 10.1016/j.jtcvs.2004.06.028]

114 **Karkouti K**, Wijeysundera DN, Beattie WS. Risk associated with preoperative anemia in cardiac surgery: a multicenter cohort study. *Circulation* 2008; **117**: 478-484 [PMID: 18172032 DOI: 10.1161/CIRCULATIONAHA.107.718353]

115 **Boodhwani M**, Rubens FD, Wozny D, Nathan HJ. Effects of mild hypothermia and rewarming on renal function after coronary artery bypass grafting. *Ann Thorac Surg* 2009; **87**: 489-495 [PMID: 19161766 DOI: 10.1016/j.athoracsur.2008.10.078]

116 **Koch CG**, Li L, Sessler DI, Figueroa P, Hoeltge GA, Mihaljevic T, Blackstone EH. Duration of red-cell storage and complications after cardiac surgery. *N Engl J Med* 2008; **358**: 1229-1239 [PMID: 18354101 DOI: 10.1056/NEJMoa070403]

117 **Murphy GJ**, Reeves BC, Rogers CA, Rizvi SI, Culliford L, Angelini GD. Increased mortality, postoperative morbidity, and cost after red blood cell transfusion in patients having cardiac surgery. *Circulation* 2007; **116**: 2544-2552 [PMID: 17998460 DOI: 10.1161/CIRCULATIONAHA.107.698977]

118 **Karkouti K**, Wijeysundera DN, Yau TM, McCluskey SA, Chan CT, Wong PY, Beattie WS. Influence of erythrocyte transfusion on the risk of acute kidney injury after cardiac surgery differs in anemic and nonanemic patients. *Anesthesiology* 2011; **115**: 523-530 [PMID: 21775877 DOI: 10.1097/ALN.0b013e318229a7e8]

119 **Ferraris VA**, Brown JR, Despotis GJ, Hammon JW, Reece TB, Saha SP, Song HK, Clough ER, Shore-Lesserson LJ, Goodnough LT, Mazer CD, Shander A, Stafford-Smith M, Waters J, Baker RA, Dickinson TA, FitzGerald DJ, Likosky DS, Shann KG. 2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. *Ann Thorac Surg* 2011; **91**: 944-982 [PMID: 21353044]

120 **Haines N**, Wang S, Undar A, Alkan T, Akcevin A. Clinical outcomes of pulsatile and non-pulsatile mode of perfusion. *J Extra Corpor Technol* 2009; **41**: P26-P29 [PMID: 19361037]

121 **O'Neil MP**, Fleming JC, Badhwar A, Guo LR. Pulsatile versus nonpulsatile flow during cardiopulmonary bypass: microcirculatory and systemic effects. *Ann Thorac Surg* 2012; **94**: 2046-2053 [PMID: 22835552 DOI: 10.1016/j.athoracsur.2012.05.065]

122 **Presta P**, Onorati F, Fuiano L, Mastroroberto P, Santarpino G, Tozzo C, Andreucci M, Renzulli A, Fuiano G. Can pulsatile cardiopulmonary bypass prevent perioperative renal dysfunction during myocardial revascularization in elderly patients? *Nephron Clin Pract* 2009; **111**: c229-c235 [PMID: 19287182 DOI: 10.1159/000208991]

123 **Baraki H**, Gohrbandt B, Del Bagno B, Haverich A, Boethig D, Kutschka I. Does pulsatile perfusion improve outcome after cardiac surgery? A propensity-matched analysis of 1959 patients. *Perfusion* 2012; **27**: 166-174 [PMID: 22312012 DOI: 10.1177/0267659112437419]

124 **Adademir T**, Ak K, Aljodi M, Elçi ME, Arsan S, Isbir S. The effects of pulsatile cardiopulmonary bypass on acute kidney injury. *Int J Artif Organs* 2012; **35**: 511-519 [PMID: 22466997 DOI: 10.5301/ijao.5000097]

125 **Kheterpal S**, Tremper KK, Heung M, Rosenberg AL, Englesbe M, Shanks AM, Campbell DA. Development and validation of an acute kidney injury risk index for patients undergoing general surgery: results from a national data set. *Anesthesiology* 2009; **110**: 505-515 [PMID: 19212261 DOI: 10.1097/ALN.0b013e3181979440]

126 **Candela-Toha A**, Elías-Martín E, Abraira V, Tenorio MT, Parise D, de Pablo A, Centella T, Liaño F. Predicting acute renal failure after cardiac surgery: external validation of two new clinical scores. *Clin J Am Soc Nephrol* 2008; **3**: 1260-1265 [PMID: 18463173 DOI: 10.2215/CJN.00560208]

127 **Wijeysundera DN**, Karkouti K, Dupuis JY, Rao V, Chan CT, Granton JT, Beattie WS. Derivation and validation of a simplified predictive index for renal replacement therapy after cardiac surgery. *JAMA* 2007; **297**: 1801-1809 [PMID: 17456822 DOI: 10.1001/jama.297.16.1801]

128 **Mehta RH**, Grab JD, O'Brien SM, Bridges CR, Gammie JS, Haan CK, Ferguson TB, Peterson ED. Bedside tool for predicting the risk of postoperative dialysis in patients undergoing cardiac surgery. *Circulation* 2006; **114**: 2208-216; quiz 2208 [PMID: 17088458 DOI: 10.1161/CIRCULATIONAHA.106.635573]

129 **Aronson S**, Fontes ML, Miao Y, Mangano DT. Risk index for perioperative renal dysfunction/failure: critical dependence on pulse pressure hypertension. *Circulation* 2007; **115**: 733-742 [PMID: 17283267 DOI: 10.1161/CIRCULATIONAHA.106.623538]

130 **Brown JR**, Cochran RP, Leavitt BJ, Dacey LJ, Ross CS, MacKenzie TA, Kunzelman KS, Kramer RS, Hernandez F, Helm RE, Westbrook BM, Dunton RF, Malenka DJ, O'Connor GT. Multivariable prediction of renal insufficiency developing after cardiac surgery. *Circulation* 2007; **116**: I139-I143 [PMID: 17846294 DOI: 10.1161/CIRCULATIONAHA.106.677070]

131 **Di Bella I**, Da Col U, Ciampichini R, Affronti A, Santucci A, Fabbri M, Sapia F, Ragni T. [Validation of a new scoring system to predict the risk of postoperative acute renal failure in cardiac surgery]. *G Ital Cardiol (Rome)* 2007; **8**: 306-310 [PMID: 17650689]

132 **Englberger L**, Suri RM, Li Z, Dearani JA, Park SJ, Sundt TM, Schaff HV. Validation of clinical scores predicting severe acute kidney injury after cardiac surgery. *Am J Kidney Dis* 2010; **56**: 623-631 [PMID: 20630639 DOI: 10.1053/j.ajkd.2010.04.017]

133 **Heise D**, Sundermann D, Braeuer A, Quintel M. Validation of a clinical score to determine the risk of acute renal failure after cardiac surgery. *Eur J Cardiothorac Surg* 2010; **37**: 710-716 [PMID: 19716313 DOI: 10.1016/j.ejcts.2009.07.018]

134 **Fortescue EB**, Bates DW, Chertow GM. Predicting acute renal failure after coronary bypass surgery: cross-validation of two risk-stratification algorithms. *Kidney Int* 2000; **57**: 2594-2602 [PMID: 10844629 DOI: 10.1046/j.1523-1755.2000.00119.x]

135 **Eriksen BO**, Hoff KR, Solberg S. Prediction of acute renal failure after cardiac surgery: retrospective cross-validation of a clinical algorithm. *Nephrol Dial Transplant* 2003; **18**: 77-81 [PMID: 12480963 DOI: 10.1093/ndt/18.1.77]

136 **Knapik P**, Rozentryt P, Nadziakiewicz P, Polonski L, Zembala M. Retrospective cross-validation of simplified predictive index for renal replacement therapy after cardiac surgery. *Interact Cardiovasc Thorac Surg* 2008; **7**: 1101-1106 [PMID: 18669528 DOI: 10.1510/icvts.2008.181438]

137 **Badreldin AM**, Doerr F, Kroener A, Wahlers T, Hekmat K. Preoperative risk stratification models fail to predict hospital cost of cardiac surgery patients. *J Cardiothorac Surg* 2013; **8**: 126 [PMID: 23659251 DOI: 10.1186/1749-8090-8-126]

138 **Parsonnet V**, Dean D, Bernstein AD. A method of uniform stratification of risk for evaluating the results of surgery in acquired adult heart disease. *Circulation* 1989; **79**: I3-12 [PMID: 2720942]

139 **Higgins TL**, Estafanous FG, Loop FD, Beck GJ, Blum JM, Paranandi L. Stratification of morbidity and mortality outcome by preoperative risk factors in coronary artery bypass patients. A clinical severity score. *JAMA* 1992; **267**: 2344-2348 [PMID: 1564774 DOI: 10.1001/jama.1992.03480170070031]

140 **O'Connor GT**, Plume SK, Olmstead EM, Coffin LH, Morton JR, Maloney CT, Nowicki ER, Levy DG, Tryzelaar JF, Hernandez F. Multivariate prediction of in-hospital mortality associated with coronary artery bypass graft surgery. Northern New England Cardiovascular Disease Study Group. *Circulation* 1992; **85**: 2110-2118 [PMID: 1591830 DOI: 10.1161/01.CIR.85.6.2110]

141 **Magovern JA**, Sakert T, Magovern GJ, Benckart DH, Burkholder JA, Liebler GA, Magovern GJ. A model that predicts morbidity and mortality after coronary artery bypass graft surgery. *J Am Coll Cardiol* 1996; **28**: 1147-1153 [PMID: 8890808 DOI: 10.1016/S0735-1097(96)00310-5]

142 **Roques F**, Nashef SA, Michel P, Gauducheau E, de Vincentiis C, Baudet E, Cortina J, David M, Faichney A, Gabrielle F, Gams E, Harjula A, Jones MT, Pintor PP, Salamon R, Thulin L. Risk factors and outcome in European cardiac surgery: analysis of the EuroSCORE multinational database of 19030 patients. *Eur J Cardiothorac Surg* 1999; **15**: 816-22; discussion 822-3 [PMID: 10431864 DOI: 10.1016/S1010-7940(99)00106-2]

143 **Roques F**, Michel P, Goldstone AR, Nashef SA. The logistic EuroSCORE. *Eur Heart J* 2003; **24**: 881-882 [PMID: 12727160 DOI: 10.1016/S0195-668X(02)00799-6]

144 **Nashef SA**, Roques F, Sharples LD, Nilsson J, Smith C, Goldstone AR, Lockowandt U. EuroSCORE II. *Eur J Cardiothorac Surg* 2012; **41**: 734-44; discussion 744-5 [PMID: 22378855 DOI: 10.1093/ejcts/ezs043]

145 **Shahian DM**, Jacobs JP, Edwards FH, Brennan JM, Dokholyan RS, Prager RL, Wright CD, Peterson ED, McDonald DE, Grover FL. The society of thoracic surgeons national database. *Heart* 2013; **99**: 1494-1501 [PMID: 23335498 DOI: 10.1136/heartjnl-2012-303456]

146 **Hickey GL**, Grant SW, Murphy GJ, Bhabra M, Pagano D, McAllister K, Buchan I, Bridgewater B. Dynamic trends in cardiac surgery: why the logistic EuroSCORE is no longer suitable for contemporary cardiac surgery and implications for future risk models. *Eur J Cardiothorac Surg* 2013; **43**: 1146-1152 [PMID: 23152436 DOI: 10.1093/ejcts/ezs584]

147 **Najafi M**, Sheikhvatan M, Sheikhfathollahi M. Discriminative power of EuroSCORE in predicting morbidity and prolonged hospital stay in an Iranian sample population. *J Teh Univ Heart Ctr* 2014; **9**: 15-19.

148 **Lameire N, Kellum JA**. Contrast-induced acute kidney injury and renal support for acute kidney injury: a KDIGO summary (Part 2). *Crit Care* 2013; **17**: 205 [PMID: 23394215 DOI: 10.1186/cc11455]

149 **McCullough PA**, Soman SS. Contrast-induced nephropathy. *Crit Care Clin* 2005; **21**: 261-280 [PMID: 15781162 DOI: 10.1016/j.ccc.2004.12.003]

150 **Aspelin P**, Aubry P, Fransson SG, Strasser R, Willenbrock R, Berg KJ. Nephrotoxic effects in high-risk patients undergoing angiography. *N Engl J Med* 2003; **348**: 491-499 [PMID: 12571256 DOI: 10.1056/NEJMoa021833]

151 **Medalion B**, Cohen H, Assali A, Vaknin Assa H, Farkash A, Snir E, Sharoni E, Biderman P, Milo G, Battler A, Kornowski R, Porat E. The effect of cardiac angiography timing, contrast media dose, and preoperative renal function on acute renal failure after coronary artery bypass grafting. *J Thorac Cardiovasc Surg* 2010; **139**: 1539-1544 [PMID: 19969314 DOI: 10.1016/j.jtcvs.2009.08.042]

152 **Kramer RS**, Quinn RD, Groom RC, Braxton JH, Malenka DJ, Kellett MA, Brown JR. Same admission cardiac catheterization and cardiac surgery: is there an increased incidence of acute kidney injury? *Ann Thorac Surg* 2010; **90**: 1418-123; discussion 1418-123; [PMID: 20971232 DOI: 10.1016/j.athoracsur.2010.04.029]

153 **Trivedi HS**, Moore H, Nasr S, Aggarwal K, Agrawal A, Goel P, Hewett J. A randomized prospective trial to assess the role of saline hydration on the development of contrast nephrotoxicity. *Nephron Clin Pract* 2003; **93**: C29-C34 [PMID: 12411756 DOI: 10.1159/000066641]

154 **Dussol B**, Morange S, Loundoun A, Auquier P, Berland Y. A randomized trial of saline hydration to prevent contrast nephropathy in chronic renal failure patients. *Nephrol Dial Transplant* 2006; **21**: 2120-2126 [PMID: 16611682 DOI: 10.1093/ndt/gfl133]

155 **Perel P**, Roberts I. Colloids versus crystalloids for fluid resuscitation in critically ill patients. *Cochrane Database Syst Rev* 2007; : CD000567 [PMID: 17943746]

156 **Ramakrishna H**, Kohl BA, Gutsche JT, Fassl J, Patel PA, Riha H, Ghadimi K, Vernick WJ, Andritsos M, Silvay G, Augoustides JG. The year in cardiothoracic and vascular anesthesia: selected highlights from 2013. *J Cardiothorac Vasc Anesth* 2014; **28**: 1-7 [PMID: 24440007 DOI: 10.1053/j.jvca.2013.10.018]

157 **Brienza N**, Giglio MT, Marucci M, Fiore T. Does perioperative hemodynamic optimization protect renal function in surgical patients? A meta-analytic study. *Crit Care Med* 2009; **37**: 2079-2090 [PMID: 19384211 DOI: 10.1097/CCM.0b013e3181a00a43]

158 **Pearse R**, Dawson D, Fawcett J, Rhodes A, Grounds RM, Bennett ED. Early goal-directed therapy after major surgery reduces complications and duration of hospital stay. A randomised, controlled trial [ISRCTN38797445]. *Crit Care* 2005; **9**: R687-R693 [PMID: 16356219 DOI: 10.1186/cc3887]

159 **McGee WT**, Raghunathan K. Physiologic goal-directed therapy in the perioperative period: the volume prescription for high-risk patients. *J Cardiothorac Vasc Anesth* 2013; **27**: 1079-1086 [PMID: 24075639 DOI: 10.1053/j.jvca.2013.04.019]

160 **Haase M**, Haase-Fielitz A, Bagshaw SM, Ronco C, Bellomo R. Cardiopulmonary bypass-associated acute kidney injury: a pigment nephropathy? *Contrib Nephrol* 2007; **156**: 340-353 [PMID: 17464145 DOI: 10.1159/000102125]

161 **Ouzounian M**, Buth KJ, Valeeva L, Morton CC, Hassan A, Ali IS. Impact of preoperative angiotensin-converting enzyme inhibitor use on clinical outcomes after cardiac surgery. *Ann Thorac Surg* 2012; **93**: 559-564 [PMID: 22269723 DOI: 10.1016/j.athoracsur.2011.10.058]

162 **Zimmerman RF**, Ezeanuna PU, Kane JC, Cleland CD, Kempananjappa TJ, Lucas FL, Kramer RS. Ischemic preconditioning at a remote site prevents acute kidney injury in patients following cardiac surgery. *Kidney Int* 2011; **80**: 861-867 [PMID: 21677633 DOI: 10.1038/ki.2011.156]

163 **Coleman MD**, Shaefi S, Sladen RN. Preventing acute kidney injury after cardiac surgery. *Curr Opin Anaesthesiol* 2011; **24**: 70-76 [PMID: 21157303 DOI: 10.1097/ACO.0b013e3283422ebc]

164 **Zangrillo A**, Biondi-Zoccai GG, Frati E, Covello RD, Cabrini L, Guarracino F, Ruggeri L, Bove T, Bignami E, Landoni G. Fenoldopam and acute renal failure in cardiac surgery: a meta-analysis of randomized placebo-controlled trials. *J Cardiothorac Vasc Anesth* 2012; **26**: 407-413 [PMID: 22459931 DOI: 10.1053/j.jvca.2012.01.038]

165 **Schetz M**, Bove T, Morelli A, Mankad S, Ronco C, Kellum JA. Prevention of cardiac surgery-associated acute kidney injury. *Int J Artif Organs* 2008; **31**: 179-189 [PMID: 18311734]

166 **Haase M**, Haase-Fielitz A, Bellomo R, Devarajan P, Story D, Matalanis G, Reade MC, Bagshaw SM, Seevanayagam N, Seevanayagam S, Doolan L, Buxton B, Dragun D. Sodium bicarbonate to prevent increases in serum creatinine after cardiac surgery: a pilot double-blind, randomized controlled trial. *Crit Care Med* 2009; **37**: 39-47 [PMID: 19112278 DOI: 10.1097/CCM.0b013e318193216f]

167 **Heringlake M,** Heinze H, Schubert M, Nowak Y, Guder J, Kleinebrahm M, Paarmann H, Hanke T, Schon J. A perioperative infusion of sodium bicarbonate does not improve renal function in cardiac surgery patients: a prospective observational cohort study. *Crit Care* 2012; **16**: R156 [PMID: 22898367 DOI: 10.1186/cc11476]

168 **Welten GM**, Chonchol M, Schouten O, Hoeks S, Bax JJ, van Domburg RT, van Sambeek M, Poldermans D. Statin use is associated with early recovery of kidney injury after vascular surgery and improved long-term outcome. *Nephrol Dial Transplant* 2008; **23**: 3867-3873 [PMID: 18628367 DOI: 10.1093/ndt/gfn381]

169 **Billings FT**, Pretorius M, Siew ED, Yu C, Brown NJ. Early postoperative statin therapy is associated with a lower incidence of acute kidney injury after cardiac surgery. *J Cardiothorac Vasc Anesth* 2010; **24**: 913-920 [PMID: 20599398 DOI: 10.1053/j.jvca.2010.03.024]

170 **Argalious M**, Xu M, Sun Z, Smedira N, Koch CG. Preoperative statin therapy is not associated with a reduced incidence of postoperative acute kidney injury after cardiac surgery. *Anesth Analg* 2010; **111**: 324-330 [PMID: 20375302 DOI: 10.1213/ANE.0b013e3181d8a078]

171 **Prowle JR**, Calzavacca P, Licari E, Ligabo EV, Echeverri JE, Haase M, Haase-Fielitz A, Bagshaw SM, Devarajan P, Bellomo R. Pilot double-blind, randomized controlled trial of short-term atorvastatin for prevention of acute kidney injury after cardiac surgery. *Nephrology (Carlton)* 2012; **17**: 215-224 [PMID: 22117606 DOI: 10.1111/j.1440-1797.2011.01546.x]

172 **Kellum JA**, M Decker J. Use of dopamine in acute renal failure: a meta-analysis. *Crit Care Med* 2001; **29**: 1526-1531 [PMID: 11505120 DOI: 10.1097/00003246-200108000-00005]

173 **Zacharias M**, Conlon NP, Herbison GP, Sivalingam P, Walker RJ, Hovhannisyan K. Interventions for protecting renal function in the perioperative period. *Cochrane Database Syst Rev* 2008; : CD003590 [PMID: 18843647]

174 **Ho KM**, Sheridan DJ. Meta-analysis of frusemide to prevent or treat acute renal failure. *BMJ* 2006; **333**: 420 [PMID: 16861256 DOI: 10.1136/bmj.38902.605347.7C]

175 **Lassnigg A**, Donner E, Grubhofer G, Presterl E, Druml W, Hiesmayr M. Lack of renoprotective effects of dopamine and furosemide during cardiac surgery. *J Am Soc Nephrol* 2000; **11**: 97-104 [PMID: 10616845]

176 **Bragadottir G,** Redfors B, Ricksten SE. Mannitol increases renal blood flow and maintains filtration fraction and oxygenation in postoperative acute kidney injury: a prospective interventional study. *Crit Care* 2012; **16**: R159 [PMID: 22901953 DOI: 10.1186/cc11480]

177 **Chappell D**, Jacob M, Hofmann-Kiefer K, Conzen P, Rehm M. A rational approach to perioperative fluid management. *Anesthesiology* 2008; **109**: 723-740 [PMID: 18813052 DOI: 10.1097/ALN.0b013e3181863117]

178 **Sezai A**, Hata M, Niino T, Yoshitake I, Unosawa S, Wakui S, Osaka S, Takayama T, Kasamaki Y, Hirayama A, Minami K. Influence of continuous infusion of low-dose human atrial natriuretic peptide on renal function during cardiac surgery: a randomized controlled study. *J Am Coll Cardiol* 2009; **54**: 1058-1064 [PMID: 19744614 DOI: 10.1016/j.jacc.2009.05.047]

179 **Yoshitake I**, Sezai A, Hata M, Niino T, Unosawa S, Wakui S, Shiono M. Low-dose atrial natriuretic peptide for chronic kidney disease in coronary surgery. *Ann Thorac Cardiovasc Surg* 2011; **17**: 363-368 [PMID: 21881323 DOI: 10.5761/atcs.oa.10.01617]

180 **Patel NN**, Rogers CA, Angelini GD, Murphy GJ. Pharmacological therapies for the prevention of acute kidney injury following cardiac surgery: a systematic review. *Heart Fail Rev* 2011; **16**: 553-567 [PMID: 21400231 DOI: 10.1007/s10741-011-9235-5]

181 **Patel UD**, Garg AX, Krumholz HM, Shlipak MG, Coca SG, Sint K, Thiessen-Philbrook H, Koyner JL, Swaminathan M, Passik CS, Parikh CR. Preoperative serum brain natriuretic peptide and risk of acute kidney injury after cardiac surgery. *Circulation* 2012; **125**: 1347-1355 [PMID: 22322531 DOI: 10.1161/CIRCULATIONAHA.111.029686]

182 **Mentzer RM**, Oz MC, Sladen RN, Graeve AH, Hebeler RF, Luber JM, Smedira NG. Effects of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery: the NAPA Trial. *J Am Coll Cardiol* 2007; **49**: 716-726 [PMID: 17291938 DOI: 10.1016/j.jacc.2006.10.048]

183 **Mitaka C**, Kudo T, Haraguchi G, Tomita M. Cardiovascular and renal effects of carperitide and nesiritide in cardiovascular surgery patients: a systematic review and meta-analysis. *Crit Care* 2011; **15**: R258 [PMID: 22032777 DOI: 10.1186/cc10519]

184 **McCullough PA**. Contrast-induced acute kidney injury. *J Am Coll Cardiol* 2008; **51**: 1419-1428 [PMID: 18402894 DOI: 10.1016/j.jacc.2007.12.035]

185 **Ashworth A**, Webb ST. Does the prophylactic administration of N-acetylcysteine prevent acute kidney injury following cardiac surgery? *Interact Cardiovasc Thorac Surg* 2010; **11**: 303-308 [PMID: 20570977 DOI: 10.1510/icvts.2010.232413]

186 **Bouman CS**, Oudemans-van Straaten HM. Timing of renal replacement therapy in critically ill patients with acute kidney injury. *Curr Opin Crit Care* 2007; **13**: 656-661 [PMID: 17975386 DOI: 10.1097/MCC.0b013e3282f0eae2]

187 **Elahi M**, Asopa S, Pflueger A, Hakim N, Matata B. Acute kidney injury following cardiac surgery: impact of early versus late haemofiltration on morbidity and mortality. *Eur J Cardiothorac Surg* 2009; **35**: 854-863 [PMID: 19216088 DOI: 10.1016/j.ejcts.2008.12.019]

188 **Pannu N**, Klarenbach S, Wiebe N, Manns B, Tonelli M. Renal replacement therapy in patients with acute renal failure: a systematic review. *JAMA* 2008; **299**: 793-805 [PMID: 18285591 DOI: 10.1001/jama.299.7.793]

**P-Reviewers:** Dizon JM, Lee T, Iyngkaran P **S-Editor:** Wen LL **L-Editor: E-Editor:**

**Table 1Definition and classification for acute kidney injury**

|  |  |  |
| --- | --- | --- |
|  | **Serum creatinine/ GFR criteria** | **Urine output criteria** |
| **RIFLE** classification |  |  |
| **Definition** | sCr rise ≥ 1.5 times baseline or GFR decrease > 25% within 7 d |  |
| **Staging** | **R (risk)** sCr rise up to 2 times bseline or GFR decrease > 25% | < 0.5 mL/kg per hour for ≥ 6 h |
|  | **I (Injury)** sCr rise up to 3 times bseline or GFR decrease > 50% | < 0.5 mL/kg per hour for ≥ 12 h |
|  | **F (Failure)** sCr rise 3 times bseline or more or GFR decrease > 75% or absolute sCr ≥ 4 mg/dL with acute rise ≥ 0.5 mg/dL | < 0.5 mL/kg per hour for ≥ 24 h or anuria ≥12 h |
|  | **L (Loss)** persistent AKI > 4 wk, need for RRT |  |
|  | **E (ESRD)** persistent loss > 3 mo, need for dialysis |  |
| **AKIN** classification |  |  |
| **Definition** | sCr rise ≥ 1.5 times baseline or ≥ 0.3 mg/dL within 48 hours |  |
| **Staging** | **1** sCr rise up to 2 times bseline or ≥ 0.3 mg/dL | < 0.5 mL/kg per hour for ≥ 6 h |
|  | **2** sCr rise up to 3 times bseline | < 0.5 mL/kg per hour for ≥ 12 h |
|  | **3** sCr rise 3 times bseline or more or absolute sCr ≥ 4 mg/dL with acute rise ≥ 0.5 mg/dL or need for RRT | < 0.3 mL/kg per hour for ≥ 24 h or anuria ≥ 12 h |
| **KDIGO** classification |  |  |
| **Definition** | sCr rise ≥1.5 times baseline within seven days or ≥ 0.3 mg/dL within 48 h or oliguria |  |
| **Staging** | **1** sCr rise up to 2 times bseline or or ≥ 0.3 mg/dL |  |
|  | **2** sCr rise up to 3 times bseline |  |
|  | **3** sCr rise 3 times bseline or more or absolute sCr ≥ 4 mg/dL with acute rise ≥ 0.5 mg/dL or need for RRT |  |

GFR: Glomerular filtration rate; AKIN: Acute Kidney Injury Network; KDIGO: Kidney Disease: Improving Global Outcomes.

|  |  |
| --- | --- |
| **Preopearative** | **Intraoperative** |
| **Patient related** |  |
| Renal dysfunction/ high sCr1 | Low venous compliance |
| advanced age | Low systemic vascular resistance |
| female gender | autoregulatory systems disturbances |
| NYHA FC IV | low output syndrome (pressor/ IABP need) |
| reduced LVEF or CHF |  |
|  | Type of surgery |
| Left main CAD | valvular |
| diabetes mellitus | re do surgery |
| poor glycemic control | emergency |
| peripheral vascular disease |  |
| COPD |  |
| Coexisting liver disease |  |
| preoperative IABP |  |
| pulmonary rales |  |
| genetic predisposition |  |
|  |  |
| **Modifiable** | **Procedure related** |
| extremes of SBP | on-pump cardiac surgery |
| sepsis | nonpulsatile flow on CPB |
|  | hypothermic CPB |
|  |  |
| Medications (NSAID, ARB) | deep hypothermic circulatory arrest |
| Contrast dye |  |
|  | duration of CPB (> 100-120 min) |
|  | perfusion pressure |
|  | hemodilution during CPB |
|  | blood transfusion |
|  | hemolysis |
|  | embolism |

**Table 2 Risk factors for acute kidney injury**

1Risk factors with higher level of evidence are in bold. NYHA FC: New York Heart Association Function class; LVEF: Left ventricle ejection fraction; CHF: Congestive heart failure; CAD: Coronary artery disease; COPD: Chronic obstructive pulmonary disease; IABP: Intra-aortic balloon pump; SBP: Systolic blood pressure; NSAID: Nonsteroidal anti-inflammatory drug; ARB: Angiotensin receptor blockers; CPB: Cardiopulmonary bypass.

**Table 3 Potential preventive measures and pharmacologic interventions in acute kidney injury**

|  |
| --- |
| **Preventive measures** |

Avoidance of nephrotoxic drugs

Angiotensin-converting enzyme inhibitors

Angiotensin receptor blockers

Hydration

Glycemic control

Maintenance of renal perfusion

Goal directed therapy

*Prevention from CI-AKI*

Hydration

N-acetyl cysteine

Bicarbonate

Timing of surgery

Ischemic preconditioning

**Pharmacologic interventions**

Fenoldopam

Nesiritide

Sodium bicarbonate

Mannitol

Atrial natriuretic peptide

Brain-type natriuretic peptide

Early postoperative renal replacement therapy

Continuous renal replacement therapy

Ultrafiltration

|  |
| --- |
|  |

CI-AKI: Contrast induced acute kidney injury.